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Abstract
Human β-defensins are a family of cationic peptides which share a pattern of 6 conserved
cysteine residues forming three disulfide bonds. Defensins are components of the innate
immune system and are involved in proinflammatory processes. The present work describes
the cloning and characterization of the cDNAs of three novel β-defensin genes (DEFB23,
DEFB27, and DEFB29) identified by bioinformatical approach. The genes are clustered in
two different contigs on chromosome 20. The genes consist of two exons and conserved exon-
intron boundary regions. From cDNA analysis, secretory signal peptides and unusually long
carboxy-terminal extensions following the β-defensin cysteine core were deduced. Expression
analysis in 28 human tissues revealed the occurrence of the transcripts in only a few organs.
The highest abundance was found in the male genital tract. A more detailed study in human
epididymis was carried out. The expression of the new β-defensin genes, studied by real-time
quantitative RT-PCR, is distinctively distributed along the functionally different segments of
the epididymal duct. In situ hybridization on human epididymal tissue sections for DEFB29
provided evidence that the expression is restricted to the epithelial cell layer, which is known
to secrete factors for sperm maturation. In addition, the immunodetection of hBD4, another
recently discovered β-defensin, showed its location in the epithelial cells, possibly in their
secretory vesicles as well as surrounding the sperm migrating within the epididymal lumen. β-
defensins are considered as antimicrobial peptides. However, hBD27 did not exhibit
antimicrobial activity against pathogenic and non-pathogenic germs. It appears that the
peptides encoded by DEFB23, DEFB27, and DEFB29 genes exert physiological functions in
the male genital tract, which may not be related to bacterial inhibition in host defense.
Keywords: β-defensin; Chromosome 20; Expression; Epididymis.
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Zusammenfassung
Humane β-Defensine bilden eine Gruppe von kationischen Peptiden, die sich durch ein
konserviertes Cysteinmotiv, welches aus 6 miteinander verbrückten Cysteinen besteht,
auszeichnet. Defensine stellen einen wichtigen Bestandteil der angeborenen Immunabwehr
dar und wirken regulatorisch in entzündungsfördernden Prozessen. Die vorliegende Arbeit
beschreibt die Identifizierung und Charakterisierung von drei neuen humanen β-Defensin-
Genen (DEFB23, DEFB27 und DEFB29) mit Hilfe eines bioinformatischen Ansatzes. Die
identifizierten Gene sind in zwei verschiedenen Regionen auf Chromosom 20 lokalisiert. Sie
bestehen aus zwei Exonen und einem konservierten Exon-Intron Übergang. cDNA-Analysen
ergaben ein für sekretorische Peptide typisches Signalpeptid sowie eine ungewöhnlich lange
dem Cysteinmotiv C-terminal folgende Aminosäuresequenz. Eine in 28 humanen Geweben
durchgeführte Expressionsanalyse zeigte, dass DEFB23, DEFB27 und DEFB29 nur in
wenigen Geweben transkribiert werden, wobei die höchste Expression im männlichem
Genitaltrakt gefunden wurde. Ausführliche Untersuchungen in epididymalem Gewebe mit
Hilfe von zeitaufgelöster quantitativer RT-PCR ergaben entlang dem Verlauf der Epididymis
eine unterschiedliche Verteilung der neu entdeckten Defensin-Gentranskripte. In situ
Hybridisierungs-Experimente an humanen epididymalen Gewebeschnitten mit cDNA-Sonden
gegen die neuen β-Defensin-Transkripte zeigten darüber hinaus, dass die Expression von
DEFB29 auf die epitheliale Zellschicht, welche zur Spermareifung notwendige Faktoren
sekretiert, beschränkt ist. Weiterhin wurde mit Hilfe von Immunhistochemie die Lokalisation
von hBD4, eines ebenfalls kürzlich identifizierten β-Defensins, entlang des männlichen
Reproduktionstrakts nachgewiesen. Dabei wurde des weiteren festgestellt, dass die
Immunreaktion gegen hBD4 sich vorwiegend in epithelialen Zellen und deren sekretorischen
Vesikeln, sowie um wandernde Spermien herum, befindet. Obwohl β-Defensine als
antimikrobielle Peptide aufgefasst werden, zeigte hBD27 keine antimikrobielle Aktivität
gegen pathogene und nicht-pathogene Keime. Es scheint somit, dass die von DEFB23,
DEFB27 und DEFB29 kodierten Peptide eine physiologische Funktion im männlichen
Genitaltrakt erfüllen, die nicht durch die Hemmung mikrobiellen Wachstums erklärt werden
kann.
Stichwörter: β-Defensin; Chromosom 20; Expression; Epididymis.
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Abbreviations
ATCC American Type Culture Collection
BCIP 5-Bromo-4-chloro-3-indolyl-phosphate
bp Base pairs
BSA Bovine serum albumin
cDNA Complementary DNA
CT Threshold cycle
Da Dalton
DAPI 4',6-Diamidino-2-phenylindole
ddH2O Bidestilated water
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DNAse Desoxyribonuclease
dNTP Desoxynucleotidetriphosphate
DTT Dithiothreitol
EDTA Ethylenediaminetetraacetic acid
ESTs Expressed sequence tags
et al et altera
EtOH Ethanol
FCS Fetal calf serum
g Gravity
Hepes N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
HPLC High performance liquid chromatography
HPRT Hypoxantine phosphoribosyltransferase
HRP Horseradish-peroxidase
IL-1 Interleukin-1
LB Luria-Bertani medium
LPS Lipopolysaccharide
NBT Nitro blue tetrazolium chloride
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PFA Paraformaldehyde
PMA Phorbol-12-myristate-13-acetate
PVDF Polyvinylidene difluoride
RNA Ribonucleic acid
rpm Revolutions per minute
SD Standard deviation
SDS Sodium dodecyl sulfate
SSC Standard saline citrate
TFA Trifluoroacetic acid
TNF-α Tumor necrosis factor α
Tris Trishydroxymethyl-aminomethane buffer
TSB Tryptic soy broth
U Units
UV Ultraviolet light
V Voltage
Note: During the present thesis, the genes are cited as DEFB whereas the peptides are termed
hBD.
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1. Introduction
1.1 Cationic antimicrobial peptides
During the last decade, several cationic peptides have been discovered on the basis of their
ability to inhibit the growth of microbial germs. Some antimicrobial peptides participate in the
innate immune response by providing a rapid first-line defense against infection. Recent
advances in this field have shown that peptides belonging to defensin and cathelicidin gene
families are of particular importance for the mammalian immune defense system.
Cathelicidins were primarily identified in mammalian myeloid cells (ZANETTI et al., 1995). They
are stored in the cytoplasmic granules of neutrophil leukocytes which release the antimicrobial
peptides upon leukocyte activation. About 20 cathelicidin members have been identified in
mammals (ZANETTI et al., 2001) but only one in humans (LARRICK et al., 1995). Cleavage of
human cathelicidin (hCAP18) liberates its C-terminal, antimicrobial domain, a peptide named
LL-37 because it begins with two leucine residues and is 37 amino acid residues in length.
Human cathelicidin is often referred to as LL-37 (GUDMUNDSSON et al., 1996).
The first human α-defensins were named human neutrophil peptides (HNP) and originally
identified as broad spectrum antimicrobial peptides (GANZ et al., 1985). As part of a study to
define antimicrobial host defense of the mammalian airway, a basic, cysteine-rich peptide
expressed in the bovine tracheal epithelium was discovered (DIAMOND et al., 1991). This
molecule, tracheal antimicrobial peptide (TAP), exhibited numerous similarities to the α-
defensins, but did not maintain the strict α-defensin cysteine motif. Shortly thereafter, 13 new
peptides were discovered in bovine neutrophils, which also showed the same six-cysteine motif
as TAP (SELSTED et al., 1993). These discoveries resulted in the creation of a second class of
defensins called β-defensins.
Mammalian defensins are a family of secreted cationic and highly disulfide-bonded peptides
which are considered as antimicrobial agents involved in host defense. Antimicrobial peptides
can be divided into numerous categories based on their primary and secondary structures but
most of them maintain certain common structural characteristics. Based on the spatial
distribution of the cysteine residues and the disulfide bridges, the vertebrate defensins are
subdivided into α-, β- and θ defensins.
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α-Defensin                           --C-C----C---------C-----------CC---
ß-Defensin                         ----C------C----C---------C------CC---
1 5432 6
1 5432 6
Figure 1. Comparison of disulfide bridges and the six-cysteine pattern of α- and β- defensins.
α-and β-defensins differ in the location and position of the cysteine residues and in their disulfide motifs. Disulfide
linkages of the bridges for α-defensins (1-6, 2-4, 3-5), and for β-defensins (1-5, 2-4, and 3-6) are shown.
In the case of θ-defensins, the peptide termed rhesus theta defensin-1 (RTD-1) is a cyclic
antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-
defensins. This cyclic peptide has six cysteine residues linking: C1 to C6, C2 to C5 and C3 to C4
(TANG et al., 1999). RTD-2 and RTD-3 were recently isolated from circulating Rhesus macaque
leukocytes (TRAN et al., 2002).
Six human α-defensins are presently known. Human neutrophil defensins are small (3.5-4 kDa)
cationic peptides (GANZ et al., 1985). They are present in large amounts in azurophilic granules
and released upon neutrophil activation (GANZ et al., 1990). Four of these homologue members
of the neutrophil defensins (HNP1 to HNP4) have been identified. Subsequent studies have
shown that neutrophil defensins also display cytotoxic activity to eukaryotic cells and a variety
of other pro- and anti-inflammatory activities (VAN WETERING et al., 1999). HNP1, HNP2, and
HNP3 might be related to the anti-HIV-1 activity of CAF (a soluble factor that suppresses HIV-1
replication) (ZHANG et al., 2002). The remaining α-defensins are HD5 and HD6. They were
found to be expressed in small intestinal Paneth cells (specialized secretory cells at the base of
the small intestinal crypts), as well as in epithelial cells of the female genital tract and are known
as mediators of antimicrobial defense (QUAYLE et al., 1998). In mouse, Paneth cells release
granules into the lumen of the crypts of Lieberkuhn in the small intestine, where the α-defensins
(cryptdins) participate in mucosal immunity. Mouse cryptdins 1-6 are potent antimicrobial
agents against certain microorganisms (OUELLETTE et al., 1992; OUELLETTE et al., 1997;
EISENHAUER et al., 1992).
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To date, six human β-defensins have been described. The first human β-defensin (hBD1) was
originally isolated from hemofiltrate (BENSCH et al., 1995). Later on, hBD2 (HARDER et al.,
1997) and hBD3 (HARDER et al., 2001) were purified from skin. The genes DEFB4 (GARCIA et
al., 2001-B), DEFB5, and DEFB6 (YAMAGUCHI et al., 2002) were recently described.
In addition, three human β-defensin-like peptides: HE2D, HE2C and HE2E, sharing the
characteristic cysteine pattern of β-defensins, were identified (VON HORSTEN et al., 2002). In
mouse, six β-defensins are known: Defb1 to Defb6 (HUTTNER et al., 1997; MORRISON et al.,
1999; BALS et al., 1999; JIA et al., 2000; YAMAGUCHI et al., 2001).
Defensins have also been described in other species (Table 1):
Table 1. β-defensins described in other species
Species defensin Authors
Monkey θ-defensin (RTD-1) TANG et al., 1999; TRAN et al., 2002
Equine α-defensin (NAP-1) COUTO et al., 1992
Bovine α-defensin (BNBD1-13) SELSTED et al., 1993
Bovine β-defensin (TAP) DIAMOND et al., 1996
Bovine β-defensin (LAP) RUSSEL et al., 1996
Bovine β-defensin (EBD) YOUNT et al., 1999
Porcine β-defensin (pBD-1) ZHANG et al., 1998; Shi et al., 1999
Sheep β-defensin (sBD1-2) HUTTNER et al., 1998
Chicken β-defensin (Gal-3) HARWIG et al., 1994
Rabbit α-defensin (NP-1) RAO et al., 1992
Rat β-defensin (RBD1) EISENHAUER et al., 1989
Plant Plant-defensin (PDF1) EPPLE et al., 1997
Insect Insect-defensin DIMARCQ et al., 1994; LEMAITRE et al., 1997; LEHRER et
al., 1999
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The amino acid sequences of human defensins and their disulfide bridges:
α-defensins
HNP1                       ACYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP2                        CYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP3                       DCYCRIPACIAGERRYGTCIYQGRLWAFCC
HNP4                       VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
HD-5                    ARATCYCRTGRCATRESLSGVCEISGRLYRLCCR
HD-6                   TRAFTCHCRR-SCYSTEYSYGTCTVMGINHRFCCL
β-defensins
hBD1       GNFLTGLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK
hBD2               GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKK
hBD3             GIINTLQKYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK
hBD4               EFELDRICGYGTARCRKK-CRSQEYRIGRCPNTYA-CCLRKWDESLLNR
hBD5    GLDFSQPFPSGEFAVCESCKLGRGKCRKE-CLENEKPGDNCRNFL--CCRQRI
hBD6                FFDDEKCNKLKGTCKNN-CGKNEELIALCQKSLK-CCRTIQPCGSIID
Figure 2. Primary amino acid sequences for the α- and β-defensins.
Bold letters indicate the conserved cysteine residues. The predicted disulfide linkages of these bridges for α-
defensins are 1-6, 2-4, 3-5, whereas the disulfide linkages of the bridges for β-defensins are 1-5, 2-4, and 3-6.
Defensins have been predominantly considered to act as antimicrobial peptides forming an early
barrier against pathogenic bacteria (SELSTED et al., 1984), fungi (GANZ et al., 1985) and viruses
(LEHRER et al., 1985; ZHANG et al., 2002). Antimicrobial cationic peptides are an important
component of the innate host defense. Antimicrobial peptides can also act in synergy with host
molecules such as other cationic peptides or proteins, and lysozymes, as well as with
conventional antibiotics. Innate immunity plays an important role in the host´s ability to avoid
the progression of a potential pathogenic infection. In the last decade, the role of cationic
peptides in antimicrobial defenses has become increasingly apparent, and there is a growing
body of evidence that their role in defense against microbes may be as important to the host as
antibodies, immune cells and phagocytes. In Drosophila, cationic antimicrobial peptides are well
recognized as the major form of defense against infection and are induced, in response to
challenge, by microbes or microbial-signaling molecules (DIMARCQ et al., 1994). In amphibians,
crustaceans, fish, birds and mammals, it is becoming increasingly clear that antimicrobial
peptides play a major role in local innate immunity, especially at mucosal and epithelial surfaces
(ANDREU and RIVAS, 1998; HANCOCK and LEHRER, 1998). Defensins are the most widely
studied family of antimicrobial peptides (COLE and GANZ, 2000). Most antimicrobial peptides
have structures that are predominantly either α-helical or β-sheet. Structure-function studies of α-
helical antimicrobial peptides have received considerable attention, partly due to their facile
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chemical synthesis. Less is known about antimicrobial or β-sheet peptides that, like defensins,
are challenging to be synthesized chemically.
1.2 Antimicrobial mechanism of action
Bacteria can be divided into two major groups, called Gram-positive and Gram-negative. The
original distinction between Gram-positive and Gram-negative was based on a spatial staining
procedure, the Gram stain, resulting from differences in cell wall structure. The Gram-negative
cell wall is a multilayered structure and quite complex, while the Gram-positive cell wall
consists of primarily a single type of molecule and is often much thicker. The activity and
selectivity of cationic peptides are determined by their mode of interaction with bacterial cell
membranes. For Gram-positive bacteria, a single cytoplasmic membrane and peptidoglycan is
involved and is easier to disrupt than Gram-negative bacteria which comprise a more complex
dual-membrane interaction. Like most antimicrobial peptides, defensins are cationic (polar)
molecules with a positive charge due to arginine and lysine residues with spatially separated
hydrophobic regions. This arrangement allows them to insert themselves into phospholipid
membranes so that their cationic regions interact with anionic phospholipid head groups and
water and their hydrophobic regions are buried within the hydrophobic membrane interior. In the
membrane they can assemble into multimeric pores. Defensins and other antimicrobial peptides
preferentially disrupt bacterial membranes that are rich in negatively charged phospholipids
(HANCOCK et al., 1998). The killing event, for both Gram-positive and Gram-negative bacteria,
is the formation of channels in the cytoplasmic membrane (Figure 3).
2
Cytoplasmic membrane
Cytoplasmic side
+  +  +  + 
Cationic peptide
1
Figure 3. General mechanism of bacteria killing by cationic peptides.
Positively charged peptides bind to the external surface of negatively charged phospholipid bilayer (cytoplasmic
membrane [1]). Then, cationic peptides form channels after localization of thinness on the bilayer (under the
influence of membrane potential peptides insert into membrane) (2), leading to leakage of cytoplasmic molecules
and cell death.
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Gram-negative bacteria are formed by the outer membrane (Lipopolysaccharide, [LPS], proteins,
phospholipids), the periplasm (lipoproteins and peptidoglycan) and additionally by the
cytoplasmic membrane. Cationic peptides interact with LPS on the surface of Gram-negative
bacteria. Because the peptides have a higher affinity for LPS than the native divalent cations
Ca2+ or Mg2+, they competitively displace these ions (HANCOCK et al., 1998). This effect causes
a disruption to the normal barrier property of the outer membrane (Figure 4). Cationic peptides
are thereby taken up across the outer membrane by a process termed self-promoted uptake
(HANCOCK et al., 1998). It is thought that the affected membrane allows passage of a variety of
molecules, including other antimicrobial and hydrophobic compounds, and facilitates the action
of the perturbing peptide itself. This fact would explain their synergy with conventional
antibiotics.
Phospholipid
+  +  +  + 
Cationic peptide
+Mg+ Porin
Outer membrane
Peptidoglycan
Lipoprotein
Periplasm
Lipid A
Polysaccharide
 INSIDE
OUTSIDE
Outer membraneProtein
Cytoplasmic membrane
Figure 4. Arrangement of the different components in Gram-negative bacteria. Self-promoted uptake of
antimicrobial cationic peptides across outer membranes of Gram-negative bacteria.
Positively charged peptides interact with negatively charged divalent-cation-binding sites on surface LPS, disrupting
these sites and allowing the cationic peptides to pass across the outer membrane.
Other mechanisms of action enhance the membrane permeability, by the formation of a barrel
stave pore (BOHEIM et al., 1994) or by a carpet mechanism (HE et al., 1996).
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The lower anionic phospholipid content of the cell membranes of higher animals may provide
relative protection from collateral damage produced by antimicrobial peptides. Nevertheless,
cytotoxic effects in mammalian cells have also been reported (LEHRER et al., 1993).
1.3 Other functions of defensins
Cationic antimicrobial peptides are well known for their ability to kill many infective agents.
However, the action of cationic antimicrobial peptides does not appear to be limited to the direct
killing of microbes. There is accumulating evidence that they have an impressive variety of
additional activities that can be expected to impact on the quality and effectiveness of innate
immune responses and inflammation. These include many of the elements of inflammatory
responses that are frequently ascribed to other agents. In fact, cationic antimicrobial peptides
have been reported to be involved in many aspects of innate host defenses associated with acute
inflammation. Some roles that cationic antimicrobial peptides may play in this process are based
on their in vitro properties. Extracellular defensins, such as hBD2, exhibit chemotactic activity
for immature dendritic cells (YANG et al., 1999), for recruitment of monocytes (TERRITO et al.,
1989) and T-cells (CHERTOV et al., 1996). Defensins can also produce an enhancement of
chemokine production and proliferative response of T helper cells (LILLARD et al., 1999),
induction of specific macrophages and activated lymphocytes (LINDEMANN et al., 1994),
induction of IL-8 production (VAN WETERING et al., 1997), regulation of complement activation
(PANYUTICH et al., 1994), enhancing antigen-specific immunity (LILLARD et al., 1999; TANI et
al., 2000), and an inhibitory effect of neutrophil defensins on tissue-type plasminogen activator
(tPA)-mediated fibrinolysis (HIGAZI et al., 1996). These functions can be seen as a combined
host defense system by linking direct bactericidal activity with recruitment of inflammatory cells
and wound healing (VAN WETERING et al., 1999). Defensins are also involved in the inhibition
of glucocorticoid production (SOLOMON et al., 1991), suppressors of ACTH activity on the
mammalian adrenal cortex (ZHU et al., 1987), and are mitogenic for fibroblasts (MURPHY et al.,
1993).
1.4 Functional genomics and mammalian defensin genes
The evolution of medical treatments has made remarkable strides aided by advances in the
technology used for drug discovery. In the early days of pharmacology, therapeutic drugs were
created from derivatives of medicinal plants. This was the case for aspirin, which was derived
from the bark of the willow tree (ARONSON, 1994). Some beneficial drugs have been discovered
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incidentally during scientific research. Over the last decade, the process of drug discovery has
become more scientific and rational. It was during this period that many of the useful drugs that
are currently still prescribed were discovered (e.g. calcium antagonists).
As researchers raced to complete the sequencing of the human genome, functional genomics
became increasingly important for the success of genomics-based drug discovery and
developmental efforts. Especially in the light of the recent description of the entire human
genome which showed that humans possess almost twice as many genes as Drosophila
melanogaster. It is not enough to know sequence information in order to utilize genomics to
develop breakthrough drugs and diagnostics. One must also understand how genes and their
products interact in pathways within the cell or the organism, and what roles they play in health
and disease. The discovery of some substances or drugs was a process that moved from
functional activity, through repeated screenings, towards an understanding of gene and molecular
structure. Using current technology and genomics, scientists can now move in the opposite
direction to that used in classical and traditional pharmacological research for new drug agents.
This technique, referred to as functional genomics, has many benefits. The drug discovery
process begins with genomic study, proceeds through screenings and ends with functional
studies to provide putative drug candidates (Figure 5).
Classical approach  
Functional activity
biological effect
Isolation of
 a certain substance
Biological role
Genomic research
Functional genomics  
Genomic research
Characterization
of the molecule
Full length cloning
Functional studies
Biological role
Drug candidate
Purification
Functional studies
Figure 5. Comparison of the classical and functional genomic approaches in the drug discovery process.
The functional genomics approach differs from the classical approach especially in the initial and final stages of the
scientific strategy.
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The genome is defined as the complete set of genes in an organism. Genomics is of increasing
interest to world leaders and was one of the topics discussed at the summit of industrialized
nations held in Okinawa in June 2000. One of the greatest challenges currently facing
pharmaceutical companies is to assimilate the vast amount of information generated by genomic
and proteomic research into drug discovery programs.
As a result, drug discovery researchers are moving into a "post-genomic", functional genomics
era. Functional genomics encompasses many traditional molecular genetics and other modern
biological approaches combined with statistical and computational analysis of the results. The
data produced by thousands of research teams all over the world are collected and organized in
databases specialized for particular subjects. The fundamental strategy in a functional genomics
approach is to expand the scope of biological investigation from studying single genes or
proteins to studying all genes or proteins at once in a systematic fashion. As a consequence of
the large amount of data produced in the field of molecular biology, most of the current
bioinformatics projects deal with structural and functional aspects of genes and proteins. A
technically challenging first priority is to generate complete sets of full-length cDNA clones and
sequences for human and model-organism genes. Other functional genomics goals include
studies of gene expression and regulation. Functional genomics, based on structural data,
promises to rapidly narrow the gap between sequence and function.
Antimicrobial peptides are generally encoded individually by genes that comprise homologous
gene families. These genes are localized on chromosomal clusters, indicating the coevolution of
different subclasses (BEVINS, 1996). To date, the defensin locus was found on chromosome
8p21-23, where the genes for both α-and β-defensins are encoded by adjacent genes. These are
two peptide families with different disulfide topology but sharing a common ancestry (LIU et al.,
1997).
Human β-defensins described so far (DEFB1 to DEFB6) have been localized on chromosome 8.
10 kb
Human
 chromosome 8
epididymis-specific
 ß-defensin
DEFB4
DEFB2
Telomere
DEFB1 DEFB5 DEFB3
DEFB6 HE2ß1
Centromere
Figure 6. Schematic view of the DEFB gene cluster on chromosome 8p23.
The arrows indicate the direction of transcription of the indicated β-defensins. The epididymis-specific genes were
located in the adjacent regions (YAMAGUCHI et al., 2002).
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Genes encoding the leukocyte α-defensins (HNP1 to HNP4) are composed of three exons. The
remaining α-defensins (HD5 and HD6) have two exons. Human β-defensins DEFB1, DEFB2,
DEFB3, DEFB4 and DEFB6 have a genomic structure formed by two exons. However, DEFB5
is coded by three exons, as was described for leukocyte α-defensins.
Examination of defensin mRNA has revealed that defensins are synthesized as precursor
molecules, comprising a signal peptide sequence, followed by the predicted mature peptide
(HARDER et al., 2001; GARCIA et al., 2001-A,-B; RODRIGUEZ-JIMENEZ et al., 2003). After
removal of the signal peptide sequence, the predicted mature peptide is yielded. Each defensin
family demonstrates substantial conservation of both amino acid and mRNA sequences in the
region encoding the signalP sequence, whereas in the mRNA this sequence identity extends into
the 5´-untranslated segment, which contains a region with more than 90% identity among
defensins of unrelated species (SCOTT and HANCOCK, 2000).
The expression of defensin genes is necessary for the natural synthesis of peptides when the
organism requires. The correlative increase of defensin mRNA with bacterial stimulation
(STOLZENBERG et al., 1997) or inflammation (GARCIA et al., 2001-B) denotes their important
role in the organism. The observation that relative levels of defensin proteins differ within the
same or different tissues and that some are inducible while others are constitutive, suggests that
defensin gene regulation is important for the maintenance of a balanced spectrum of
antimicrobial activity (KAISER and DIAMOND, 2000). Therefore, the identification of the
regulatory elements involved in defensin gene expression is of interest.
The expression of human α-defensins was considered as constitutive (VAN WETERING et al.,
1999). In the case of β-defensins, the expression of DEFB1 has been considered constitutive in
the kidney, pancreas, the female reproductive tract, and the airways (ZHAO et al., 1996; MCCRAY
and BENTLEY, 1997). Other authors determined that due to the low expression of DEFB1 in
human endometrial epithelial cells, a final conclusion of its regulation was prevented (KING et
al., 2002). On the other hand, it has recently been demonstrated that in human peripheral blood,
DEFB1 and DEFB2 genes were transcribed and translated following the induction of LPS or
heat-inactivated bacterial cells, whereas the DEFB3 gene was not expressed. The inducible
expression of DEFB1 and DEFB2 genes showed interindividual variability, but in general
DEFB1 showed a higher level of expression after the mentioned stimulation. This report showed
that HNP1, HNP2, and HNP3 genes were constitutively transcribed in blood cells (FANG et al.,
2003). The human peptide hBD1 was originally isolated from hemofiltrate (BENSCH et al.,
1995). DEFB2 is expressed in epithelia, for instance in skin and lung (HARDER et al., 1997) and
can be induced upon epithelial stimulation by inflammatory cytokines (BECKER et al., 2000;
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KING et al., 2002). In addition, bacteria and fungi also strongly enhance DEFB2 expression
(HARDER et al., 1999). Moreover, hBD2 (HARDER et al., 1997) and hBD3 (HARDER et al., 2001)
were purified from skin. DEFB3 expression was found in epithelial (e.g. lung, trachea) and non-
epithelial tissues (e.g. heart, skeletal muscle) (HARDER et al., 2001; GARCIA et al., 2001-A; JIA et
al., 2001). DEFB3 is induced by TNF-α and bacteria (HARDER et al., 2001), as well as γ-
interferon (GARCIA et al., 2001-A). Recent results showed that the expression for DEFB4 was
mainly expressed in testis and neutrophils, being inducible in lung epithelial cells by adding
PMA (GARCIA et al., 2001-B). In addition, an inhibition of the stimulated expression of mRNA
for hBD3 but not hBD1 and hBD2 by corticosteroids, was observed (DUITS et al., 2001). It is
well known that corticosteroids have an important influence on the regulation of the reproductive
organ function.
The group of β-defensin-like peptides was described as a human sperm antigen which was
initially identified during a screening for epididymis-specific transcripts (OSTERHOFF et al.,
1994). These gene products are included in the mRNA species that are specifically transcribed
within the proximal region of human epididymis and in no other tissue or species examined. The
Human Genome Project localized the HE2 gene on the short arm of chromosome 8, directly
adjacent to the DEFB3 and DEFB4 genes. The HE2 gene gives rise to multiple differentially
spliced mRNA populations that encode a group of small cationic secretory peptides. Recently,
the occurrence of multiple human HE2 transcripts in the human male genital tract was
confirmed, including minor mRNA variants (VON HORSTEN et al., 2002). The homologue
sequences had previously been shown only in animal species (FRÖHLICH et al., 2001). Three of
these splicing variants named HE2C, HE2D, and HE2E share the conserved cysteine pattern of
β-defensins (VON HORSTEN et al., 2002). Concerning the regulation of these β-defensin-like
peptide genes, HE2ß2 and HE2γ are also androgen-regulated human proteins (HAMIL et al.,
2000). They have already been shown to be secreted to the epididymal lumen and bind
specifically to the sperm surface (HAMIL et al., 2000).
1.5 The male reproductive tract
The male reproductive system produces the male reproductive cells, the sperm, and contains an
organ that deposits the sperm within the female. The male genitals include the testis, the ductuli
deferentes, the ejaculatory ducts, and the penis, the prostate and the bulbourethral glands.
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Spermatic cord
Blood vessels and nerves
Seminiferous tubule
Lobule
Septum
Tunica albuginea
Tunica vaginalis
Cavity of tunica vaginalis
Cauda epididymis
Corpus epididymis
Tubulus rectus
Rete testis
Ductus deferens
Efferent ductule
Caput epididymis
Figure 7. Vertical section of testis to show the arrangement of the different anatomical structures.
The testes are two glandular organs which secrete the semen; they are suspended in the scrotum
by the spermatic cords. The testis is invested by two tunics: the tunica vaginalis and tunica
albuginea (see Figure 7). The glandular structure of the testis consists of numerous lobules. They
differ in size according to their position, those in the middle of the gland being larger and longer.
Each lobule consists of convoluted tubes, the seminiferous tubule. They are supported by loose
connective tissue which contains groups of interstitial cells. Each tubule consists of a basement
layer formed of laminated connective tissue containing numerous elastic fibers with cells
between the layers and covered externally by a layer of flattened epithelioid cells. Within the
basement membrane, epithelial cells are arranged in several concentric layers, which are not
always clearly separated. Among these cells the spermatozoa may be seen in different stages of
development (see Figure 8). The spermatogenesis process consists of three sequential phases of
cell proliferation and differentiation. First, there is an extensive multiplication and proliferation
of spermatogonial stem cells to produce an optimal number of spermatogonia which give rise to
primary spermatocytes and to maintain a pool of stem cells. Second, the primary spermatocytes
undergo the meiotic prophase, followed by the first meiotic division resulting in the formation of
two secondary spermatocytes, each undergoing the second meiotic phase to produce four haploid
round spermatids (ABOU-HAILA and TULSIANI, 2000). Finally, there is a gradual remodeling of
the nuclear and cellular components of round spermatids during transformation into sperm cells
by a process referred to as spermiogenesis (DE KRETSER and KERR, 1994). In addition to these
Introduction                                                                                                                                                             20
three layers of cells, others are seen which are termed the supporting cells (Sertoli cells). They
are elongated and columnar, and project inward from the basement membrane towards the lumen
of the tube. Sertoli cells contribute to provide the specific environment required by the process of
spermatogenesis (ABOU-HAILA and TULSIANI, 2000).
Round spermatidSpermatocyte
Cell of Sertoli
Spermatogonium
Spermatozoa
Figure 8. Transverse section of a tubule of the testis of a rat. Arrangement of the different cells of rat testis.
The epididymis is a single convoluted tubule, which is divided into three major regions based on
histological appearance of the epithelium: the proximal (caput), the medial (corpus) and the
distal (cauda) epididymis from which the vas deferens emerges. Spermatozoa move from the
seminiferous tubules within each testis, through the rete testis and the efferent ductules, to the
epididymis, and hence to the vas deferens. The epididymal duct is lined by a pseudostratified
columnar epithelium, with tall columnar cells and shorter basal cells giving the appearance of
two rows of nuclei. This pseudostratified epithelium lines not only the epididymis but also the
vas deferens. The columnar cells are characterized by apical stereocilia. The basal cells are
believed to be precursors of the columnar cells. The columnar epithelial cells lining the
epididymis absorb testicular fluid, secrete a variety of factors for sperm cell maturation and
maintenance, and remove damaged sperm and residual bodies (KING, 2002). The sperm migrate
within the epididymal lumen (see Figure 9). In the most proximal region of the epididymis (the
proximal caput), spermatozoa exhibit unidirectional orientation and are often aligned parallel to
one another (DE KRETSER and KERR, 1994). This is taken as an indication that spermatozoa from
this region of epididymis lack motility and their movement depends exclusively on the flow of
epididymal fluid. Spermatozoa from the corpus region exhibit some degree of motility, but they
are only capable of rotatory movements (ABOU-HAILA and TULSIANI, 2000). However,
spermatozoa from the cauda epididymis exhibit forward motility and are considered functionally
competent cells (YANAGIMACHI, 1994).
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Ciliated epithelium
Spermatozoa in lumen
Figure 9. Section of epididymis of guinea-pig
The epididymis consists of a series of highly coiled zones, separated by connective tissue and
distinguished by epithelial cell morphology and their pattern of expression possibly reflecting the
vectorial and progressive functions related to sperm concentration, maturation, transport, and
storage (YEUNG et al., 1993; HOLSTEIN, 1969; HAMILTON, 1990). The molecular basis of these
functions is poorly understood. However, it has become increasingly clear that regional
differences along the length of the duct play a role in epididymal physiology and that region-
specific gene expression is involved in the formation of these differences. During the past ten
years, a large number of genes have been cloned and analyzed, being involved in the
establishment and maintenance of a unique and highly regionalized expression pattern along the
duct. A large number of epididymis-expressed genes have been cloned and analyzed at the
molecular level, most of them having been characterized by a distinct temporal and spatial
expression pattern within the organ (RODRÍGUEZ et al., 2001). There is a long-standing interest in
this regionalized pattern since it may serve as a major molecular basis underlying epididymal
physiology. Most mammalian spermatozoa do not have the ability to move progressively or to
fertilize an egg by the time they leave the testis. They require a posttesticular maturation process
which takes place in the epididymis (BEDFORD, 1994). Most probably, factors of epididymal
origin act in concert with constitutional changes to spermatozoa, which together permit full
sperm function. The evidence that sperm maturation and storage require exposure to the specific
microenvironment of the epididymis has been reviewed elsewere (COOPER et al., 1986; JONES,
1998; TURNER, 1995; HINTON et al., 1996; NOLAN and HAMMERSTEDT, 1997). The functions of
specific components of this microenvironment are still poorly understood.
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Immunolocalization and fluorescence in situ hybridization have revealed that the principal cells
are mainly responsible for the synthesis and secretion of proteins (HERMO et al., 1994). It has
been suggested that may result in the sperm encountering a unique and ever-changing luminal
fluid environment as they progress through the epididymis (COOPER, 1995). The order in which
the spermatozoa come into contact with the specific epididymal secretions may be crucial for the
resultant physiological effects (CORNWALL and HANN, 1995). Thus, the longitudinal subdivision
into morphologically and functionally distinct zones may be fundamental to the process of sperm
maturation and storage. The epididymal phase of sperm maturation is then followed by further
changes occurring during ejaculation and finally in the female genital tract. The biochemical and
functional modifications during the passage through the female tract are collectively referred to
as capacitation (SUAREZ, 1987; YANAGIMACHI, 1994). Mammalian fertilization is the net result
of a complex set of molecular events before penetration and fusion with the egg.
1.6 Aim of the work
Using functional genomics as a scientific strategy, a search was directed to discover new genes
codifying peptides with the classical cysteine motif of β-defensins. To study their distribution
and expression pattern, including the expressing cell type, gene induction and their
immunolocalization in the human organism were programmed to be determined.
Material and methods                                                                                                                                              23
2. Material and methods
2.1 Material and organisms
2.1.1 Sterilization of material
Thermostable materials and solutions (glass, plastic tubes, polypropylene-tips) were sterilized for
20 min at 121°C and 1 bar in an autoclave (Bioclav 3.021001, Schütt Laboratories). Cellulose-
acetate phthalate (CAP)-membrane filter, sterile filters (Filtropur, Sarstedt, 0.22 µm) were also
used for solution sterilization. Metal and ceramic equipment was sterilized for 3 h at 180°C with
dry heat. The solutions used in molecular biology were prepared using Milli-Q water (Milli-QUF
plus, Millipore). Analysis quality water (Difco, Merck, Roth and Sigma-Aldrich) was required
for several assays.
2.1.2 Instruments and devices
Precision pipettes (Eppendorf), magnetic plates and other machines were used:
Picture camera: -EDAS 290. Documentation system with software Kodak 1D V. 3.5.0 (Kodak)
DNA-Sequencer: -Capillary electrophoresis-sequencer PRISM 310 Genetic analyser
(AppliedBiosystems [ABI])
Real-Time PCR: -PRISM 7700 Sequence Detection System (ABI)
Microplate-Reader: -Microplate Autoreader EL 311 (Bio-Tech Instruments)
Protein gel electrophoresis: -Xcell SureLock Electrophoresis cell (Novex)
Spectrophotometer: -DU 640 (Beckman)
Sterilization: -Bioclav 3.021001 (Schütt Labortechnik)
Thermocycler: -GeneAmp PCR System 2400 (ABI)
Ultrasonoscope: -Vibra cell (Sonics and Materials)
Ultraturrax: -Ultra-Turrax T25 (Janke and Kunkel)
Microscope: -Zeiss axiophot (Zeiss)
Thermomixer: -Eppendorf thermomixer 5436 (Eppendorf)
Hybridizer oven: -Roller-Blot HB-3D (Techne)
Centrifuge: -Biofuge 28 RS (Heraeus sepatech)
-Hettich mikro rapid (Hettich)
Water bath: -GFL (Labortechnik)
Speed bac: -MC2L-60°C/Univapo 150H (Uniequip/Unicryo)
Vortex: -IKA Labortechnik (Janke and Kunkel)
Microtome: -HM 340 (Microm)
Refrigerator: -UF85-360T (Colora)
-Economic cooler (Bosch)
Microwave: -700 W (Bosch)
Cell culture incubator: -IG150 (Jouan)
Clean bench: -8511 (Kottermann)
Miniprep culture: -4340 illuminated refrigerator incubator shaker (Innova)
Western blotting -XCell Sure Lock gel chamber, (Invitrogen)
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2.1.3 Kits and enzymes
Different kits were used for the routine work in molecular biology, this material allows faster
and safer work. Applications, commercial denominations and companies are shown (Table 2):
Table 2. Kits used in molecular biology.
Application Kit
Isolation of genomic DNA QIAamp DNA Mini Kit (Qiagen)
Isolation of total RNA RNeasy Mini Kit (Qiagen)
Plasmid isolation NucleoSpin Plus (Macherey-Nagel)
DNA purification from agarose gel NucleoSpin Extract (Macherey-Nagel)
Purification of DNA fragments NucleoSpin Extract (Macherey-Nagel)
DNA sequencing PRISM BigDye Terminator Cycle Sequencing Kit (ABI)
Immunohistochemistry Vectastain Universal Elite ABC kit (Vector Laboratories)
Real-time PCR (TaqMan) assay TaqMan Universal PCR Master Mix (ABI)
TaqMan PCR Core Reagent Kit (ABI)
2.1.4 Oligonucleotides
Oligonucleotides were provided by MWG-Biotech or TIB-Molbiol (Table 3).
Table 3. Overview of the different oligonucleotides.
Denomination Oligonucleotides sequences 5´!3´ Application
β-Tub-11 TTCCCTGGCCAGCTSAANGCNGACCTNCGCAAG Degenerated primer (sense) for
housekeeping gene β-tubulin
β-Tub-21 CNCCTCGCCNGTGTACCAGTGNANGAAGGC Degenerated primer (antisense)
for housekeeping gene β-tubulin
Intro-β-Tub for TCAGATCTTTCGGCCGGACAACTT Primer (sense) for detecting β-
Tubulin intronic sequence.
Test for genomic contamination
Intro-β-Tub rev TACCTGGATTCCAGCTTCTAGAAC Primer (antisense) for detecting
β-Tubulin intronic sequence.
Test for genomic contamination
M13/pUC forward
sequencing primer
AGTCACGACGTTGTAAAACGACGGCCAGT Sequence primer for cloning
vector pGEM T
M13/pUC reverse
sequencing primer
CAATTTCACACAGGAAACAGCTATGACCATG Sequence primer for cloning
vector pGEM T
DEFB16 Race
inner
CAGCACTTTTGATCATTTGGGCAGGTT 5´-Race primer for DEFB16.
(Investigation of exon 1)
DEFB16 Race
outer
CATATTCTCTGCAGGCGTTTCTGCACAT 5´-Race primer for DEFB16.
(Investigation of exon 1)
DEFB22 Race
inner
TGCTGTGGTAAATGTGGCTGGTCCTT 5´-Race primer for DEFB22.
(Investigation of exon 1)
DEFB22 Race
outer
TGCTGTGGTAAATGTGGCTGGTCCTT 5´-Race primer for DEFB22.
(Investigation of exon 1)
DEFB23 F in situ TTCATTTTGGGCTGCCTTAG Primer (sense) for DEFB23.
Confirmation of sequence and in
situ hybridization
Material and methods                                                                                                                                              25
DEFB23 R in situ ACTGGGAGCTTCATCTGCAT Primer (antisense) for DEFB23.
Confirmation of sequence and in
situ hybridization
DEFB23 Probe TM FAM-     CTGACTCCAGGTGGCACCCAAAGATG
TAMRA
TaqMan probe (sense) for
DEFB23
DEFB23 F TM CTTTGACTGTGCTGCTGCTCTT TaqMan primer (sense) for
DEFB23
DEFB23 R TM TGTAACGGCATTTGCCATAAAG TaqMan primer (antisense) for
DEFB23
DEFB27 F in situ GTGCAGTTCACTGGACCAAAAG Primer (sense) for DEFB27.
Confirmation of sequence and in
situ hybridization
DEFB27 R in situ TGCTCGAAGGTCATTTTAAGGAT Primer (antisense) for DEFB27.
Confirmation of sequence and in
situ hybridization
DEFB27 Probe TM FAM-     TTGCAATTCTGCTGTTCCAGAAACCCA-
TAMRA
TaqMan probe (sense) for
DEFB27
DEFB27 F TM CCATGGGGCTCTTCATGAT TaqMan primer (sense) for
DEFB27
DEFB27 R TM CTGCAGATTTTCCTGCAATGTC TaqMan primer (antisense) for
DEFB27
DEFB29 F in situ CAACCATGAAGCTCCTTTTTCC Primer (sense) for DEFB29.
Confirmation of sequence and in
situ hybridization
DEFB29 R in situ TGACTGATGACAGAGGAAACAGTTC Primer (antisense) for DEFB29.
Confirmation of sequence and in
situ hybridization
DEFB29 Probe TM FAM-
CCAGGTGAACACAGAATTTATTGGCTTGAGA-
TAMRA
TaqMan probe (sense) for
DEFB29
DEFB29 F TM TCCTATCTTTGCCAGCCTCAT TaqMan primer (sense) for
DEFB29
DEFB29 R TM CATCCACATTGCAGTGATCC TaqMan primer (antisense) for
DEFB29
GAPDH TM for CCTGCACCACCAACTGCTTA TaqMan primer (sense) for
housekeeping gene GAPDH
GAPDH TM rev CATGAGTCCTTCCACGATACCA TaqMan primer (antisense)for
housekeeping gene GAPDH
GAPDH TM probe FAM-CCTGGCCAAGGTCATCCATGACAAC-
TAMRA
TaqMan probe (sense) for
housekeeping gene GAPDH
1) S = (G + C) and N = (A + T + G + C). Nomenclature of nucleotides according to IUPAC.
2) FAM reporter (6-carboxy-fluorescein); TAMRA quencher (6-carboxy-tetramethyl-rhodamine).
2.1.5 Use of organisms and plasmids
During the present work in molecular and cell biology, the use of bacteria and plasmids was
necessary, e.g. during the cloning process. The plasmid pGEM-T (Promega) allows selection by
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blue/white screening. For transformation, Epicurian Coli XL10-Gold were used as competent
cells.
2.2 Recombinant DNA isolation, cloning, and sequencing
2.2.1 DNA modification enzymes and restriction endonucleases
Different enzymes were used to modify DNA (during the PCR, cloning process, etc.) as well as
for the reverse transcription reactions to produce cDNA from mRNA. The percentage of
restriction endonucleases was less than 10% of the final volume avoiding inhibitory effects due
to high concentrations of glycerin used to store the enzymes.
Table 4. Enzymes used during DNA manipulation.
Enzyme Commercial denomination
Reverse transcriptase SuperScript II RT (Life Technologies)
DNA polymerase Taq Platinum DNA-polymerase (Life Technologies)
AmpliTaq-Gold (ABI)
DNA nuclease DNAse I Amp Grade (Life Technologies)
Restriction endonucleases Pst I, Not I (Life Technologies)
RNase-inhibitor RNasin (Promega)
DNA ligase T4 DNA ligase (Promega)
2.2.2 Standard polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a rapid procedure for in vitro enzymatic amplification of
specific segments of DNA (SAIKI et al., 1985). PCR has spawned a multitude of experiments that
were previously impossible. The present work includes different applications, for instance the
amplification of fragments from genomic DNA or cDNA as well as nucleotide sequencing.
Components of the PCR reaction:
10% 10 × PCR-buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl)
2 mM MgCl2
200 nM Oligonucleotide primer (sense and antisense)
200 mM dNTPs (200 mM each of dATP, dCTP, dGTP and dTTP)
7.5  200 ng Template DNA (cDNA, plasmid or genomic DNA)
0.75 U Taq Platinum DNA-polymerase (Life Technologies)
add until 100% ddH2O
Final volume in a standard PCR was 50 µl.
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The parameters of a PCR depend on the characteristics of the sequence object of study (e.g.
length of oligonucleotides used, length of amplicons, etc). A standard PCR was followed
according to the following guidelines:
1. 1 cycle
         Initial denaturation of the DNA                                         98°C                                       3 min
2. 36 cycles
Denaturation 94°C 10 s
Annealing of the primers 52-60°C 30 s
         Extension                                                                           72°C                                          50 s
3. 1 cycle
         End of the extension                                                          72°C                                       8 min
4. End of the reaction 4°C ∞
98°C 94°C
3 min
10 s
52-60°C
30 s
72°C 72°C
50 s 8 min
∞
36 cycles1 cycle 1 cycle
4°C
The annealing temperature of DEFB23, DEFB27, DEFB29 for confirmation of the mRNAs was
55°C for 12 s, followed by an extension step at 72°C for 45 s. The bands of interest were
amplified using cDNA produced from mRNA extracted from human testis. The polymerase
chain reaction was performed using a GeneAmp PCR System 2400 Thermocycler (ABI), and
Taq platinum DNA-polymerase. This enzyme has the advantage of thermostability, and the
ability to stand the repeated heating and cooling inherent in PCR and to synthesize DNA at high
temperatures with an efficiency of approximately 1000 bp/min.
2.2.3 Colony PCR
Colony PCR is a very efficient method to identify the clones containing the plasmid with the
insert of interest and to differentiate them from the other clones not incorporating it. This
technique constitutes an alternative method of selection to the classical way of restriction
analysis. After transformation using competent cells, the positive colonies are selected according
to their color. The pGEM-T cloning vector produces a functional lacZ- gene α fragment that
allows the formation of a β-galactosidase enzyme which results in the formation of blue colonies
on Xgal/IPTG indicator plates. Cloning of DNA fragments into the polylinker site prevents
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production of a functional lacZ-α fragment (white colonies), allowing a rapid identification of
positive clones. The bacteria were cultivated onto an agar plate (supplied with 100 µg/ml
ampicillin) and simultaneously incorporated into the PCR tube. The amplification of the genetic
material was achieved by using pUC/M13 sense and antisense oligonucleotides (Table 3). These
primers include the polylinker regions of the plasmid used (pGEM-T) amplifying 250 bp (in the
case of negative colonies) or 250 bp plus the length of the insert (in the case of the positive
colonies).
PCR premastermix I (amount per reaction):
2 µl 10 × PCR buffer
0.8 µl 50 mM MgCl2
17.5 µl ddH2O
PCR mastermix II (amount per reaction):
1 µl 10 × PCR buffer
0.6 µl MgCl2 (50 mM)
0.25 µl dNTPs (10 mM)
0.25 µl Oligonucleotide primer (10 µM)
7.5 µl ddH2O
0.15 µl Taq Platinum DNA-polymerase
Using sterile material, the chosen bacterial colonies were cultivated by applying the selected
clones with a tip onto the surface of an agar plate. The same tip was subsequently used to
provide the template in an individual PCR tube with 20 µl PCR premastermix I. Then the cycler
heated the samples at 98ºC for 3 min before decreasing the temperature to 52-60ºC. The
thermocycler was paused in order to include 10 µl of the second part of the mastermix (PCR-
mastermix II) during the pre-PCR. The rest of this process coincides with the standard PCR
described previously (see 2.2.2) except for the initial denaturation. Once the procedure was
finished, the positive clones were selected, inoculated and grown in 3 ml LB medium with
ampicillin at 37°C/ overnight.
PCR-Mastermix I
(including bacteria)
98°C
3 min 72°C
8 min
∞
94°C
10 s
52-60°C
30 s
72°C
50 s
36 cycles1 cycle 1 cycle
4°C
52-60°C
pause
PCR-Mastermix II
PRE-PCR  
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2.2.4 RACE-PCR
Rapid amplification of 5´- cDNA ends by polymerase chain reaction (5´- RACE-PCR) was used
to determine unknown 5´- cDNA ends. A RACE PCR kit (Clontech) was used to identify exon 1
for pseudogenes DEFB16 and DEFB22, and to complete their nucleotide sequences in the 5'-
direction (GLADMAN et al., 1988). Thus, cDNA amplification was performed with a specifically
designed antisense primer from the known sequence of public DNA clones (ESTs). The use of
Taq-polymerase has the effect of adding a poly A to the 5´-end of amplicons, that would
facilitate the assembly of a complementary anchor (dT) 16 V primer (AP1) in this position of the
sequences. This fact creates a double strand and, in consequence, an amplification of the
unknown 5'-termini. The specificity of this reaction was increased by a second PCR (inner-PCR),
using the specific DEFB16, DEFB22 race primer and the inner AP2 primer. AP2 is
complementary to AP1, assembling in the inner location. Both reactions were executed in
accordance with the manufacturers´ instructions. The temperature of annealing during the
extension decreased progressively by two degrees in all subsequent stages, accepting the
possibility of non-specific amplifications. On the other hand, this PCR program guaranteed
obtaining amplification products.
Outer PCR
1.      Initial denaturation of the mix                                              94°C                                 5 s
2. 3 cycles
Denaturation 94°C 5 s
         Annealing of the primers and extension                               72°C                               45 s
3. 5 cycles
Denaturation 94°C 5 s
         Annealing of the primers and extension                               70°C                               45 s
4. 31 cycles
Denaturation 94°C 5 s
         Annealing of the primers and extension                               68°C                               45 s
5. 1 cycle
         Annealing of the primers and extension                               68°C                            8 min
6. End of the reaction 4°C ∞
94°C 94°C
5 s 5 s 72°C
45 s
∞
3 cycles1 cycle 5 cycles
94°C
5 s
45 s
70 °C
31 cycles
94°C
5 s
45 s
68°C 68°C
8 min
1 cycle
4°C
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Inner PCR
1.      Initial denaturation of the mix                                        94°C                                      5 s
2. 5 cycles
Denaturation 94°C 5 s
         Annealing of the primers and extension                         72°C                                    45 s
3. 35 cycles
Denaturation 94°C 5 s
         Annealing of the primers and extension                         68°C                                    45 s
4. 1 cycle
         Annealing of the primers and extension                         68°C                                  5 min
5. End of the reaction 4°C ∞
94°C 94°C
5 s 5 s 72°C
45 s
∞
5 cycles1 cycle 35 cycles
94°C
5 s
45 s
68°C 68°C
5 min
1 cycle
4°C
2.2.5 Agarose gel electrophoresis
Agarose gel electrophoresis is a simple and highly effective method for separating, identifying,
and purifying DNA fragments. A gel is prepared with an appropriate concentration of agarose for
the size of DNA fragments to be separated. Electrophoresis was performed at 80-120 V, for a
period of time that allowed optimal separation. For visualization of DNA, ethidium bromide
(0.1 µg/ml) was applied previously into the gel. The fragments can be visualized directly upon
UV light and photographed with a Kodak EDAS 290 documentation system. DNA ladders
(1 kbp or 100 bp ladder, Life Technologies) were used for estimation of fragment length.
Ethidium bromide solution: 1 mg/ml Ethidium bromide in ddH2O.
50 × TAE buffer:
2 M Tris
100 mM EDTA
1 M Glacial acetic acid
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5 × Loading buffer
40% Glycerin
20 mM Tris-HCl [pH 8.0]
2 mM EDTA
0.1% (w/v) Bromphenol blue
2.2.6 Extraction of DNA fragments from agarose
DNA extraction was performed with the aid of NucleoSpin Extract Kits from Macherey-Nagel
(VOGELSTEIN and GILLESPIE, 1979). Using a clean scalpel, DNA fragments were excised from
the gel. For each 100 mg agarose gel, 300 µl buffer NT1 were added in order to dissolve the
agarose. The samples were incubated for 10-15 min at 50°C, loaded on a NucleoSpin Extract
tube and placed in a 2 ml centrifuge tube. After a centrifugation step at 6000 × g for 60 s, the
flowthrough was discarded. The NucleoSpin Extract tubes were again placed in the centrifuge
tube. Then, 700 µl buffer NT3 were added and the samples were centrifuged at 12.000 × g for
60 s to remove buffer NT3. NucleoSpin Extract tubes were again placed in the centrifuge tube
and centrifuged at 12.000 × g for 2-5 min, to remove of residual ethanol which would inhibit
subsequent reactions. After placing the NucleoSpin Extract tubes in a clean 1.5 ml centrifuge
tube, 50 µl of ddH2O were added to elute the DNA by centrifuging at 12.000 × g for 60 s.
2.2.7 DNA ligation
In general terms, cloning vectors are selected according to the size of the insert of interest.
During this work, the pGEM-T vector (Promega) was used routinely. The PCR fragments were
modified with Taq platinum DNA polymerase (Life Technologies). This enzyme adds a
nontemplated nucleotide (usually dA) to the ends of PCR fragments. The vector pGEM-T
(Promega) provides terminal thymidines that fit with the nontemplated nucleotide dA allowing
the ligation process.
Composition of the ligation reaction:
6 µl (0.1 to 5 µg) Extracted products from agarose gels
1 µl 10 × Ligation buffer
2 µl (20 ng) pGEM-T (Promega)
1 µl (3 U) T4 DNA ligase (Promega)
After mixing all reagents properly, ligation was performed overnight at 4°C. Then, the vector
(insert included) was transformed into Epicurian Coli XL10-Gold Ultracompetent Cells.
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2.2.8 Competent cell preparation
The production of transformational competent cells was performed by incubation of bacteria
with MgSO4 (NISHIMURA et al., 1990). The solution was sterile-filtered through an 0.2 µm filter
before adding it to the LB-Medium (Medium A). This solution was prepared freshly. Then, 1 ml
of medium A was removed and stored at 20°C while the remaining medium was stored at room
temperature, overnight.
Simultaneously, an overnight culture of Epicurian Coli XL10-Gold Ultracompetent Cells in 5 ml
of LB-Medium (without antibiotics) was incubated at 37°C with shaking at 200 rpm.
The next day, 1 ml of the culture obtained overnight was incubated in 100 ml medium A, at
37°C. The cells grew steadily until they reached OD578nm = 0.55 (blank: LB-medium).
Afterwards the culture was placed on ice for 10 min and was subsequently centrifuged at
4000 × g, at 4°C in 50 ml tubes. Then the supernatant was discarded and the pellet was
resuspended carefully in 1 ml medium A previously stored at 20°C. After complete
resuspension of the pellet, 5 ml of medium B was added, drop by drop and under constant
agitation of the tube. Afterwards, the preparation was placed on ice again and aliquoted in 100 µl
portions into prechilled 1.5 ml tubes. The aliquots were deposited as deeply as possible at 80°C.
The prepared E.coli cells became competent after being kept at 80°C for approximately one
week.
LB (Luria-Bertani) medium (see cell and yeast culture).
Medium A:
LB medium with: 10 mM MgSO4
0.2% Glucose
MgSO4-solution and glucose were filtered previously.
Medium B:
LB medium with: 36% Glycerin
12% Polyethyleneglycol (PEG 8000)
12 mM MgCl2
The PEG 8000 was dissolved in glycerin and added to the LB-Medium (with magnesium).
2.2.9 Bacterial cell transformation
Aliquots of 100 µl competent cells were slowly defrosted and 5 µl from the ligation reaction
were included in the tube containing the bacteria. The solution was subsequently incubated on
ice for 30 min, to allow the recombinant plasmid DNA to attach to the bacterial membrane. After
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warming the samples to 42°C for 90 s, the tubes were immediately transferred on ice for 5 min.
The goal of this step is to produce a thermo-shock, allowing the recombinant plasmid to be
included into the cells. Subsequently, 900 µl of SOC-Medium was added to the ligation reaction
tube for further incubation at 37°C for 60 min, with gentle shaking. The bacteria were
centrifuged at 400 × g for 5 min. The supernatant was removed and 40 µl of the remaining
solution were applied on an agarose plate, containing 100 µg/ml ampicillin together with 40 µl of
IPTG and 40 µl of X-Gal. Ampicillin selects the growing colonies with resistance to this
antibiotic. The three compounds were mixed and spread on the plates. The selected colonies
were used to perform colony PCR (see 2.2.3).
SOC Medium:
2% Casein
1% Yeast extract
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4
10 mM NaCl
20 mM Glucose
The medium was autoclaved; pH 7.0 was adjusted by adding 5 N NaOH.
IPTG solution (sterilized by filtration):
100 mM isopropyl-1-thio-β-D-galactoside in ddH2O
X-Gal solution:
2% (w/v) 5-bromo-4-chloro-3-indolyl-β-D-galactoside in N. N-dimethylformamide
Selection-agar plate:
LB-medium with: 1.5% agar (Sigma A-5054)
100 µg/ml ampicillin
Afterwards the solution was autoclaved, 100 µg/ml ampicillin was added when the temperature was below 50°C and pH
7.4 was adjusted using 1 N NaOH.
2.2.10 Miniprep double-stranded DNA isolation
The isolation of plasmid DNA from E. coli cells, containing recombinant plasmids, was performed
using the alkaline lysis procedure (BIRNBOIM and DOLY, 1979). Bacteria were cultured overnight in
3 ml LB-medium with 3 µl ampicillin (100 µg/ml). Subsequently, 2 ml of culture were centrifuged
at 12.000 × g for 30 s. Lysis was performed by treatment with a solution containing sodium dodecyl
sulfate (SDS) and NaOH, (SDS denatures bacterial proteins, NaOH denatures chromosomal DNA).
NucleoSpin Plasmid, (Macherey-Nagel, Germany) is designed for the rapid small-scale preparation
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of high-purity plasmid DNA. After centrifugation, the pellets were resuspended carefully in 250 µl
buffer A1 including RNase A. The lysis buffer A2 was applied to the preparations for 5 min at room
temperature. The lysis was stopped by adding buffer A3. The suspensions were always mixed
gently by inverting the tubes 6-8 times and incubated on ice for 5 min. The resulting solutions were
centrifuged at 12.000 × g, for 10 min, at 4°C. Thereby, bacterial proteins and genomic DNA were
sedimented. Placing NucleoSpin columns in a 2 ml centrifuge tube, the supernatants from the
previous step were loaded onto the columns and centrifuged at 12.000 × g for 60 s. Then, the
flowthroughs were discarded. The columns were washed with 0.5 ml buffer AW. Columns were
centrifuged at 12.000 × g for 60 s and washed by adding 700 µl of buffer A4. After centrifugation at
12.000 × g for 3 min, the flowthroughs were removed. This step was repeated in order to eliminate
residual ethanol. Placing the NucleoSpin columns in a new centrifuge tube, the DNA was eluted by
adding 50 µl water and a final centrifugation was performed at 12.000 × g for 1 min.
2.2.11 Sequencing of DNA
The dideoxy or enzymatic method (SANGER et al., 1977) was used to identify DNA fragments. The
sequencing reaction was performed using a GeneAmp PCR System 2400 Thermocycler. A
synthetic oligonucleotide primer was annealed on a single-strand DNA template after a previous
denaturation step. The sequencing reactions were always produced using a PRISM Big Dye
Terminator Cycle Sequencing Kit (ABI).
Components of a sequencing reaction:
4 µl BigDye Terminator Ready Reaction Mix
1 µl Oligonucleotide primer (10 pmol/µl)
x µl template DNA (7.5 ng)
Add ddH2O until 20 µl.
Program of temperatures used for amplification of the sequences.
1. 25 cycles
Denaturation 96°C 10 s
Annealing of the primers 54°C 5 s
         Extension                                                                        60°C                                  4 min
2. 1 cycle
         End of the extension                                                       60°C                                  8 min
3. End of the reaction 4°C ∞
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96°C
10 s
54°C
5 s
60°C
4 min
∞
25 cycles 1 cycle
4°C
60°C
8 min
Once the sequencing reaction was finished, 80 µl ddH2O were added to every single reaction. The
precipitation of the DNA was performed at 4°C by adding the mix to a 1.5 ml tube containing 15 µl
2 M sodium acetate solution (pH 5.2) and 250 µl 95% ethanol. Tubes were incubated on ice for
10 min. The samples were centrifuged at 12000 × g for 15 min to allow sedimentation of DNA.
After discarding the supernatant, pellets were washed with 250 µl 70% ethanol and centrifuged
again at 2000 × g for 5 min. The resulting products were freeze-dried and resuspended again in
20 µl ddH2O. At this point the samples were applied to the PRISM 310 Genetic Analyzer (ABI)
sequencer. The parameters for the electrophoresis were 30 s of probe injection and 15 kV at 50°C.
The sequences were analyzed using V3.4.1-Software (ABI).
2.3 Analysis of gene expression
RNA is an unstable molecule and the major source of failure in any attempt to produce RNA is
contamination by ribonucleases. RNases are very stable enzymes and generally require no cofactors
to function. Therefore, a small amount of these enzymes in RNA preparation would create future
problems. To avoid tedious and current time-consuming methods involving the use of toxic
substances, RNeasy Kit (Qiagen) was used, providing a fast and simple method for obtaining RNA.
2.3.1 Isolation of total RNA from animal tissues and cells
For the isolation of RNA from animal tissues the following tissues were purchased from Clontech
Laboratories (Palo Alto, CA. USA): small intestine, skin, testis (including epididymis), placenta,
trachea, heart, skeletal muscle, liver, thyroid gland, pancreas, uterus, lung, kidney, salivary
gland, prostate, brain, cerebellum, adrenal gland, and mammary gland. Tissue samples from
esophagus, jejunum, colon, rectum, bladder as well as from different stomach segments (antrum,
fundus, corpus) were kindly provided by Professor Dr. Markus Buechler (Heidelberg, Germany)
and PD Dr. Helmut Friess (Bern, Switzerland). For every organ object of study, 500 mg were
homogenized. For this purpose, tissues were placed in a mortar with liquid nitrogen and divided into
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small pieces. Tissues were shredded using an Ultra-Turrax T25 rotor-stator homogenizer. RNA
isolation from cell lines was performed using 500 µl lysis buffer, (RLT-buffer, Qiagen) and 1% β-
mercaptoethanol. Prior to isolation, QIAshredder columns (Qiagen) were used for material
homogenization. Culture cells or tissues were homogenized in a denaturing solution containing 4 M
guanidine thiocyanate and β-mercaptoethanol in the lysis buffer, causing RNAses and protein
denaturation. One volume of 70% ethanol was then added to the resulting mixture. Subsequently,
700 µl of sample were applied to an RNeasy mini spin column placed in a 2 ml collection tube and
centrifuged at 8000 × g for 15 s. To remove undesirable compounds, 700 µl buffer RW1 were
added onto the RNeasy column and centrifuged at 8000 × g for 15 s. An ethanolic solution (buffer
RPE) was added in order to achieve a clean extraction of RNA. The resulting mixture was
centrifuged at 8000 × g for 15 s. In addition, and after removing the flowthrough, the samples were
centrifuged at 8000 × g for 2 min for the removal of residual ethanol which would interfere with
subsequent reactions. Afterwards, the RNeasy columns were transferred to new 1.5 ml collection
tubes. RNase-free water was added and RNA was eluted by centrifugation at 8000 × g for 60 s.
Finally an aliquot of this RNA solution was used for measuring the concentration by photometric
analysis (see 2.3.2). The resulting RNA solution was stored at -80°C.
2.3.2 Determination of DNA/RNA concentration
For some experiments, e.g. reverse transcription and DNA sequencing, it is necessary to determine
the nucleic acid concentration in solution. For this purpose, the absorption of an aqueous solution
was measured in a quartz tray, with 1 cm of thickness at a wavelength of 260 nm. The nucleic acid
concentration (C) was determined by the following formula:
c[ng/µl] = OD260 × ε × V
The extinction-coefficient ε for single-strand DNA or RNA is 0.04 and for double-strand 2dDNA is 0.05, while V
describes the dilution. OD260 is the optical density at 260 nm.
In addition, the purity of a nucleic acid preparation can be determined by UV absorption. The ratio
from the measured optical densities at 260 nm and 280 nm (OD260/OD280) indicates whether the
nucleic acid solution is contaminated by protein remain. Pure DNA preparations indicate a ratio of
1.8, whereas clean RNA solutions would reflect a ratio of 2.0.
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2.3.3 Synthesis of cDNA from RNA
The sensitive method of the PCR can be applied not only to genomic DNA, but also to cDNA
molecules to indirectly examine RNA transcripts in different tissues. A prerequisite for such an
investigation is transcribing RNA into complementary DNA (cDNA) using a viral reverse
transcriptase. To avoid contamination with genomic DNA, RNA preparations were routinely
digested with DNase I before use in cDNA synthesis. Then, 1.5 µg freeze-dried RNA were
solved in 7 µl RNase-free water. Subsequently, a mix formed by 1 µl RNasin (Promega),
10 × DNase reaction buffer and 5 µl DNase I (Life Technologies) was added. DNA digestion
was stopped after 15 min by adding 1 µl 25 mM EDTA. After incubation at 65°C for 10 min the
enzymes involved were completely inactivated. The solutions were treated with 500 ng random
hexamer primers. The mix was denatured at 70°C for 10 min and rapidly cooled down on ice for
5 min, in order to enable assembly of the hexamer primers. Subsequently, 6 µl of 5 × 1 st strand
buffer, 3 µl of 0.1 M dithiothreitol (DTT) and 1 µl dNTP mix (10 mM) were added and mixed
carefully. The solution was incubated for 2 min at 42°C. The reverse transcription started by adding
200 U SuperScript II (Life Technologies). The resulting products were incubated for 50 min at
42°C. The reaction was stopped by inactivating the enzyme at 70°C for 15 min. The concentration
of the complementary DNA produced was calculated from the RNA amount used.
An estimation of the cDNA quality was determined in two following control experiments. A PCR
with a β-tubulin pair of primers checked the efficiency of cDNA, and a second PCR with intronic β-
tubulin-primers tested putative genomic contamination.
2.3.4 Real-Time PCR (TaqMan)
For the accurate and reproducible quantification of transcripts in cells and tissues, real-time PCR
(TaqMan) was performed using a PRISM 7700 Sequence Detection System (ABI). The principle of
this method is based on the use of the 5´nuclease assay described by HOLLAND et al., 1991. It
consists of detecting specific PCR products based on the use of dual-labeled fluorogenic probes
(LEE et al., 1993). The probe is designed to hybridize within the target sequence. Then a signal is
generated and accumulated during PCR cycling in a manner proportional to the concentration of
amplification products. The method uses the 5´nuclease activity of Taq polymerase to cleave a
nonextendible hybridization probe during the extension phase of PCR. The measurement of
fluorescence in each sample provides a homogeneous signal, which is specifically associated with
the amplified target and quantitatively related to the amount of PCR products. High specificity and
sensitivity in nucleic acid quantification was achieved by choosing adequate primers and probe
sequences. Annealing temperature of the chosen oligonucleotide primers was around ten degrees
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below the annealing temperature of the probe. Oligonucleotides must not contain many Cs and Gs
at the 5´or 3´ends of the primers and probes, because it would impair the correct assembly of the
sequences. These rules are important for avoiding problems such as inefficient cleavage of probes.
Figure 10. Principle of the TaqMan PCR.
(A) At the beginning of the PCR the oligonucleotide probe labeled with reporter dye (R) and quencher (Q) hybridize
to the target sequence. By the spatial proximity of the two fluorescence dyes a fluorescence resonance energy
transfer (FRET) takes place, and therefore the fluorescence signal is suppressed. (B) During the elongation phase the
Taq DNA polymerase meets the bound probe. A transition structure during the displacement reaction activates the
5'- 3'- exonuclease activity of the Taq DNA polymerase and leads to the hydrolysis of the probe (C). The distance
between reporter coloring material and quencher, increased now, allows the FRET to be interrupted and a
fluorescence signal becomes measurable. The Taq DNA polymerase is symbolized by a grey ellipse, assembled
oligonucleotide primer by thick lines. Energy of the reporter dye material becomes measurable as a fluorescence
signal (λ=518 nm).
The dual-labeled fluorogenic probe is formed by a fluorescent dye which serves as a reporter FAM
(6-carboxy-fluorescein) and its emission spectrum is quenched by the second fluorescent dye,
TAMRA (6-carboxy-tetramethylrhodamine). When the probe is intact, fluorescent energy transfer
occurs and the reporter dye fluorescent emission is absorbed by the quenching dye. During the
extension phase of the PCR cycle, the fluorescent hybridization probe is cleaved by the 5´-3´
nucleolytic activity of the DNA polymerase. On cleavage of the probe, the reporter dye emission is
no longer efficiently transferred to the quenching dye, resulting in an increase of the reporter dye
fluorescent emission spectra.
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The nuclease degradation of the hybridization probe releases the quenching of the FAM fluorescent
emission which is measured by the detection system. To calculate the quantity of output cDNA,
the amplification plot is examined early in the reaction, at a point that represents the exponential
phase of product accumulation, in which the fluorescence intensities are detected according to
their wavelengths. This is achieved by assigning an arbitrary threshold that is based on the
variability of the base-line data. Once the threshold is chosen, the point at which the
amplification plot crosses the threshold is defined as CT (threshold cycle). CT is reported as the
cycle number at this point. The CT value is predictive of the quantity of input target. Because of
the necessity of three different oligonucleotides (2 primers and the probe), the dependency of a
detectable fluorescence signal makes the real-time PCR a highly specific assay. Moreover, a
possible amplification of genomic sequence was additionally prevented by the use of probes
which hybridize at the exon-intron boundary position.
The modifications of the fluorescence intensities during a real-time PCR were measured with the
help of the PRISM 7700 Sequence Detection of System (ABI). All necessary probes were
labeled with 6-carboxy-fluorescein (FAM) as reporter and with 6-carboxy-tetramethyl-
rhodamine (TAMRA) as quencher, becoming excited by the ionized argon laser of the PRISM
7700 (λ=488 nm). The emission spectra of the fluorescence coloring materials were measured
automatically within the range of 500-660 nm and converted by a CCD camera (charge-coupled
device) into data points, being interpreted by computer.
Oligonucleotide primer and probes were derived with the program primer express (ABI) and
from the companies MWG (primer) and TIB MOLBIOL (probes). The use of an endogenous
reference gene can also prevent errors which result from an inaccurate estimation of total RNA
concentration and quality in the initial sample. The expression of a housekeeping gene, in this
case GAPDH (glyceraldehyde-3-phosphate-dehydrogenase), is commonly used as an
endogenous reference mRNA target.
TaqMan PCR program:
1. 1 cycle
         Uracil-N-Glycosylase-reaction                                            50°C                               2 min
2. 1 cycle
         Initial denaturation                                                               95°C                             10 min
3. 45 cycles
Denaturation 95°C 15 s
Annealing process and
         Amplification of sequences                                                  60°C                               1 min
4. End of the reaction 25°C ∞
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The absorption spectra were obtained during the amplification of the target sequence.
For each PCR reaction the following reagents were needed:
12.5 µl 2 × TaqMan universal PCR master mix (ABI)
250 nM Oligonucleotide primer (250 nM each primer)
250 nM Probe (5´-FAM/3´-TAMRA labeled oligonucleotide)
2.0 µl cDNA (Template)
Final volume: 25 µl.
2.3.5 Quantification of endogenous expression
The quantification of the transcription of DEFB23, DEFB27 and DEFB29 was achieved by using
a standard curve as the basic method of quantification. The external calibration curve requires
that the absolute concentration of the standard is known by some independent method
(photometric analysis).
Recombinant DNA plasmids, containing the respective amplicon of interest, were used to
prepare absolute standards. Thus, serial dilutions of recombinant plasmid containing a copy
number of the target sequence (DEFB23, DEFB27, DEFB29 or housekeeping gene) were
prepared. The correlation of the dilutions in the standard curve is indicated by a correlation
coefficient which must be R > 0.97 to provide an exact evaluation method. The number of
copies/µl of the molecule of interest can be determined by the following mathematical formula.
I. Transformation of the concentration [µg/µl] in [pmol/µl]:
DNA  1 
 1
10 
 660
 DNA  g
6
pmol
Ng
pg
pg
pmol
=×××
µ
µ
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II. Transformation of [pmol/µl] in [number of molecules /µl]:
[pmol DNA/µl] × NA= [molecules of target sequence/µl]
N = Number of nucleotide pairs, including insert; NA = 6,023 × 1023 (Avogadro´s number) (number of copies /mol);
660 mol/g is the average molecular weight of a nucleotide pair.
2.4 Culture of human cells and microorganisms
2.4.1 Culture of prokaryotic cells and yeast
The cultivation of bacteria was based on the general guidelines indicated by SÜßMUTH et al.,
1999. The description of the germs used and their growth conditions are shown in Table 5.
Table 5. Germs used for the investigation of the antimicrobial activity of hBD23, hBD27, and hBD29.
Bacteria Strain Medium Gram
staining
Temperature of culture
Staphylococcus carnosus TM300 LB + 37°C
Staphylococcus aureus ATCC25923 TSB + 37°C
Streptococcus pneumoniae DSM11865 TSB + 37°C
Escherichia coli DSM96440 LB - 37°C
Escherichia coli DSM1103 LB - 37°C
Klebsiella pneumoniae DSM681 LB - 37°C
Pseudomonas aeruginosa DSM1128 LB - 37°C
Culture media:
LB (Luria Bertani):
1.0% Casein (Sigma C-0626)
0.5% Yeast extract (Sigma Y-4000)
0.5% NaCl
Solids were disolved in water (pH 7.4 adjusted by adding 1N NaOH). The solution was autoclaved.
TSB-Medium (Tryptic Soy Broth):
0.3% Tryptic Soy Broth (Sigma T-8261)
99.7% Bidest water.
The solid was disolved (pH 7.2 adjusted by adding 5 N NaOH). The solution was autoclaved.
Material and methods                                                                                                                                              42
2.4.2 Cell culture
2.4.2.1 Cell culture conditions
Human cell lines were cultured following the recommendations summarized by LINDL et al., 2000.
The cells were cultured under standard conditions at 37°C and 5% CO2. Cultures stored in liquid
nitrogen were thawed at 37°C in a water bath and washed with culture medium (20% FCS) in order
to remove the freezing medium (DMSO).
After sedimentation for 5 min at 120 × g , cells were resuspended in 20 ml culture medium and
transferred to 75 cm² culture flasks. When 80-90% confluence was reached, cells were washed
twice with PBS and treated with 3 ml trypsin/EDTA solution for 2-4 min at 37°C.
The time of tryptic treatment depends on the cellular type. The reaction was stopped by adding
10 ml medium containing 10% FCS. The supernatant was discarded after centrifugation. Then, cells
were resuspended in fresh culture medium. Surplus cells were frozen, stored at -80°C for 48 h and
transferred to liquid nitrogen (-196°C) in suitable freezing containers (Cryovial, Roth).
Freezing medium: The appropriate cell line medium plus:
20%  FCS
2 mM  L-Glutamine
100 µg/ml Penicillin/Streptomycin
10% DMSO
The addition of 10% of DMSO prevents the process of crystallization.
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Table 6. Short description of the human cell lines used in cell culture.
Cell line Origin/Tissue/Morphology Reference
HUH-7 Human hepatoma cell line. Adherent cells
grow as monolayer
Established from surgical liver of a 57-year-
old patient (NAKABAYASHI et al., 1982)
HaCaT Human keratinocyte cell line. Adherent cells
grow as monolayer
Spontaneous immortal human keratinocytes
(BOUKAMP et al., 1988)
SAEC 6043 Human lung cell line. Adherent cells grow as
monolayer
Established from surgical lower airways of a
54-year-old female patient. Company
Cellsystems, number Cc-2547
RPMI 2650 Human nasal septum squamous cell carcinoma.
Cells grow as monolayer
From pleural effusion of a 52-year-old man,
DSMZ-Deutsch GmbH
HS-1 Human normal testis. Adherent cells grow as
monolayer
Male Caucasian. ECACC
EPLC-272H Human epidermoid lung carcinoma. Adherent
cells grow as monolayer
Established from surgical lung specimens of
a 54-year-old patient, DSMZ-Deutsch GmbH
TE671 Human rhabdomyosarcoma. Adherent cells
grow as monolayer
Muscle cells from medulloblastoma, DSMZ-
Deutsch GmbH
A549 Human lung carcinoma. Adherent cells grow as
monolayer
Established from an explanted lung tumor
removed from a Caucasian man in 1972
HEK 293 Human embryonic kidney. Adherent cells grow
as monolayer
Cell biochemistry clinic institute neurology.
Hamburg. Germany
NCI 417 Small cellular bronchial carcinoma, suspension
cell line
ATCC number: CRL 5809
Table 7. Companies and their corresponding products used in cell culture.
Medium and additional cell culture material Company and catalog number
Dulbecco´s Modified Eagle Medium (DMEM),
4.5 g/l glucose
Life Technologies, 41965-039
HAM F12 Life Technologies, 21765-029
RPMI 1640 Life Technologies, 31870-025
BEGM bullet kit Clonetics, CC-3170
SAGM bullet kit Cell Cystems CC-3118
Fetal calf serum (FCS) BioWhittaker, 14-701F
Ultroser G Life Technologies, 15950-017
PBS Dulbecco´s Life Technologies, 14190-094
Trypsin/EDTA (1 ×) Life Technologies, 25300-054
10.000 µg/ml Penicillin/Streptomycin (100 ×) Life Technologies, 15140-130
200 mM (100 ×) L-Glutamine Life Technologies, 25030-024
75 cm²  cell culture flask with filter Sarstedt, 83.1813.002
6-well cell culture plate, ∅ 35 mm Corning Costar, 3516
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Table 8. Cell lines and their corresponding culture medium
Cell line Culture medium
HaCaT RPMI 1640, 100 µg/ml Penicillin/Streptomycin, 2 mM L-Glutamine, 10% FCS
HUH-7 DMEM, 100 µg/ml Penicillin/Streptomycin, 2 mM L-Glutamine, 10% FCS
NCI-N 417 RPMI 1640, 100 µg/ml Penicillin/Streptomycin, 2 mM L-Glutamine, 10% FCS
A 549 10% Dulbecco´s MEM/10% FCS
RPMI-2650 DMEM (with Earle´s salts) /10% FCS/ 1 × non-essential amino acids
TE-671 80-85% DMEM/15-20% FCS
EPLC-272H 80% RPMI 1640/20% FCS
HS-1 DMEM/2 mM Glutamine/10% FCS
HEK-293 DMEM, 100 µg/ml Penicillin/Streptomycin, 2 mM L-Glutamine, 10% FCS
SAEC 6043 SAGM bullet kit
2.4.2.2 Cell stimulation
To investigate an in vitro inducing transcription for the new β-defensin genes, different human cell
lines were incubated for 24 h with proinflammatory mediators. Cells were split on a 6-well culture
dish. After 24 h, the culture reached 60-70% confluence. Following the appropriate stimulation
times, cells were washed once with PBS. The cells were stimulated in three wells in parallel. The
incubation with culture medium served as negative control.
Table 9. Description of the stimuli used in cell culture.
Stimuli Company Final concentration Cat. number
Interleukin 1α TEBU GmbH 20 ng/ml medium 016200-01A
Interferon γ TEBU GmbH 40 ng/ml medium 016300-02
Lipopolysaccharide (E.coli) Sigma 10 µg/ml medium L-2654
Phorbol-12-myristate-13-acetate Sigma 10 ng/ml medium P-8139
TNF-α TEBU GmbH 20 ng/ml medium 016300-01A
With the exception of Interferon γ (PBS), Interleukin 1α (100 mm trichloroethylene, 100 mM
NaCl, pH 8.0) and PMA (DMSO), the rest of the proinflammatory mediators were disolved in
water (ACS degrees, Sigma).
2.5 In situ hybridization
The study of gene products using biochemical and molecular techniques often requires tissue
samples containing a considerable amount of the target molecule. However, many interesting
genes are expressed either in a minority of cells in complex tissues or for only brief periods of
time during the differentiation of an organism or tissue.
In order to identify the specific location and the expressing cell type of the novel human β-
defensins in the epididymal tract, in situ hybridization was performed on human epididymal
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tissue sections. The procedure was based on the fundamentals of non-radioactive in situ
hybridization using digoxigenin-11-UTP-labeled cRNA probes described previously
(TSUKAMOTO et al., 1991).
2.5.1 Tissue preparation
Epididymal tissues (kindly provided by A. Prützmann, St. Franziskus Hospital,
Mönchengladbach, Germany) were fixed in 4% paraformaldehyde (PFA) and embedded in
paraffin. Tissues were washed in PBS overnight at 4°C. A further dehydration of the tissues was
performed as follows:
Table 10. Solutions and conditions used during the dehydration process.
Solution Condition
50% EtOH Movement, overnight, room temperature
70% EtOH Movement, overnight, room temperature
80% EtOH Movement, overnight, room temperature
90% EtOH Movement, overnight, room temperature
96% EtOH Movement, overnight, room temperature
After dehydration, tissues were placed in toluol, with movement, at room temperature, overnight,
and subsequently embedded in Paraplast, keeping the tissues at 65°C, for 18 h. The preparation
solidified by a sudden drop in temperature.
2.5.2 Preparation of paraffin sections
Paraffin sections were cut (5 µm) using a microtome (Microm. HM340. Heidelberg, Germany)
and spread on slides (SuperFrost Plus, Menzel-Glaeser, Germany). Then, sections were
deparaffined 3 times for 7 min using Rothistol (Roth), and rehydrated as follows:
Table 11. Solutions and conditions used during the rehydratation process.
Solution Condition
96 % EtOH 1 min, room temperature
90% EtOH 1 min, room temperature
80% EtOH 1 min, room temperature
70% EtOH 1 min, room temperature
50% EtOH 1 min, room temperature
Residual ethanol was removed by washing in PBS. Sections were incubated at 37°C for 30 min
with 20 µg/ml proteinase K (Sigma, P2308). This step allows the RNA targets to be more
accessible to the RNA probes. Samples were washed and put on a course of retrieval by
embedding them in 0.2% glycin/PBS for 5 min. Sections were fixed in 4% PFA/0.2%
glutaraldehyde and washed again in PBS.
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2.5.3 Riboprobe preparation
Full-length cDNAs of ET-1, DEFB23, DEFB27, and DEF29 were cloned into the pGEM-T
vector (Promega) in forward and reverse direction. The plasmids were linearized by enzymatic
digestion.
Table 12. Matherial used for the linearization process.
cDNA Amount of enzyme Corresponding buffer
ET-1 8 µl NotI 150 U React buffer 2 (Gibco BRL/Life)
DEFB23 8 µl NotI 150 U React buffer 2 (Gibco BRL/Life)
DEFB27 8 µl PstI 150 U React buffer 3 (Gibco BRL/Life)
DEFB29 8 µl PstI 150 U React buffer 3 (Gibco BRL/Life)
For linearization, an additional 48 µl of water, ACS reagent (Aldrich, Germany) and 2 µl
albumin BSA (20 mg/ml) (MBI Fermentas) were added. The samples were incubated at 37°C for
2 h and afterwards purified using the phenol/chloroform/isoamyl alcohol (25:24:1) extraction.
After centrifugation at 8000 × g for 20 min, samples were transferred to a solution containing
50 µl 7.5 M NH4Ac and 250 ml 100% EtOH. After 1 h at 80°C, tubes were centrifuged at
8000 × g for 20 min. Pellets were washed with 80% EtOH and centrifuged again under the same
conditions. After drying the pellets, samples were resuspended in 15 µl of DEPC water. DNA
was quantified by photometric analysis and adjusted in order to obtain 1 µg during the reverse
transcription reaction:
Reverse transcription reaction:
1 µg linearized cDNA
2 µl 0.1 M DTT (Gibco BRL/Life)
4 µl 5 × transcription buffer (Promega)
2 µl 10 × DIG nucleotides (Roche)
1 µl RNasin 10000 U (40 U/µl)
1 µl T7 RNA-polymerase (1000 U) (Roche)
The vector pGEM-T offers the possibility to generate the riboprobes using two enzymes (T7- or
SP6- RNA polymerase). Nevertheless, DIG-labeled RNA probes were generated using only T7-
RNA polymerase (Roche) in order to reduce the differences in efficiency, caused by using two
different enzymes. The solutions were incubated at 37°C for 2 h. After adding 2 µl DNase I
(1U/µl, Life Technologies) the samples were incubated at 37°C for 10 min.
Samples were subsequently purified by precipitation with 2 µl of 0.2 M EDTA, 2.5 µl 4 M LiCl,
and 75 µl 100% EtOH. Samples were kept at 80 C for 2 h. Then, they were centifuged at
8000 × g for 15 min at 4°C and washed twice with 100 µl EtOH 70%. Afterwards, the tubes
were centrifuged under the same conditions and the pellet was resuspended in 50 µl of DEPC-
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water. Samples were stored at 80°C for no longer than six months. The efficiency of the
riboprobe production was checked by standard electrophoresis (see 2.2.5).
2.5.4 Hybridization procedure
In situ hybridization was performed on slices from human testis, caput, corpus, and cauda
epididymis. Prehybridization was carried out for 1 h at 55°C in prehybridization solution.
Hybridization was performed with a suitable amount of labeled riboprobes (3-5 µl, according to
the results of a previous electrophoresis) in 100 µl of prehybridization solution at 55°C in a
humidity chamber for 16 h. The slides were subsequently rinsed in 2 × SSC (17.5 g NaCl, 8.8 g
sodium citrate, 800 ml ddH2O) pH 4.5 for 5 min followed by two washing steps in 2 × SSC
pH 4.5/50% deionized formamide at 50°C for 15 min. Sections were treated with blocking
solution for 1 h at room temperature. The slides were subsequently incubated overnight at 4°C
with an anti-DIG-antibody conjugated to alkaline phosphatase (Roche) diluted 1:1500 in
blocking solution. The process continued with two washing steps in 0.02% Tween/PBS and
equilibration in NTMT twice for 5 min.
Prehybridization solution:
50% Deionized formamide
5 × SSC
1% Blocking reagent (Boehringer)
10 mM Maleic acid pH 7.5
15 mM NaCl
0.1% EDTA
0.1% Tween 20
0.1% CHAPS (Sigma)
0.1% Heparin (Sigma)
1 mg/ml Yeast tRNA
Blocking solution:
2% Blocking reagent (Boehringer)
0.02% Tween 20
1% Normal sheep serum in PBS, pH 7.5
NTMT:
50 mM Tris/HCl
100 mM NaCl
50 mM MgCl2
0.05% Tween 20
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2.5.5 Signal detection
Detection was performed using nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate
(NBT/BCIP, Sigma) for 2 h at room temperature. Slides were washed, fixed in 4%
paraformaldehyde and mounted in Mowiol solution.
Mowiol solution:
48 g Mowiol 488 [Sigma-Aldrich 32.459-0]
21.1% Glycerol/ 0.1 M Tris/HCl, pH 8.5
DAPI staining was performed by adding DAPI 1 µg/ml for 3 min. Subsequently slides were
washed in PBS and visualized by fluorescent microscopy.
Additional controls, like omitting the probe or pretreatment with 100 mg/ml RNase A for
10 min, were also included in this study. The pretreatment with RNase A was performed to
eliminate the signal produced by RNA. This would omit the positive signal.
2.6 Chemical synthesis of β-defensins
2.6.1 Solid-phase peptide synthesis
The β-defensin peptides used in this study were synthesized in the Peptide Synthesis Division of
IPF PharmaCeuticals GmbH by Dr. Enno Klüver and Dr. Axel Schulz. The following part will
briefly state the synthesis strategies for the defensin peptides.
All peptides were synthesized according to the principle of solid-phase peptide synthesis
(MERRIFIELD et al., 1986) with the use of the fluorenylmethoxycarbonyl (Fmoc)-protecting
group on an automated peptide synthesizer 433A (Applera). Synthesis was performed using
preloaded TentaGel resins (Rapp Polymere). TG R PHB-Lys(Boc) Fmoc for hBD27, hBD23 and
hBD29 with standard HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-
hexafluorophosphate)/HOBt (1-hydroxybenzotriazol) activation in N-methylpyrrolidinone on a
scale of 0.1 mmol. All cysteine residues were trt-protected. The resulting peptidyl resins were
treated at room temperature with a mixture of trifluoracetic acid / ethanedithiol / water (94:3:3,
v/v/v, 40 ml/g resin) for 3-4.5 h and then precipitated by filtration into ice cold tert-
butylmethylether (TBME). The resulting products were separated by centrifugation, washed with
TBME and dried under vacuum. The crude peptides were dissolved in diluted acetic acid and
loaded onto a preparative Vydac C18 column (47 × 300 mm, 15 - 20 µm, flow rate 40 ml/min;
solvent A, 0.07% TFA; solvent B, 0.07% TFA in acetonitrile/H2O 80:20; UV detection at
215 nm; with the following gradient: 20-60% B in 80 min). The fractions containing the desired
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peptides, as detected by mass spectrometry and analytical C18 HPLC, were pooled and
lyophilized. hBD23 and hBD29 were used in their linear forms, whereas hBD27 was folded
using a 0.1 M NH4HCO3 buffer containing 2 mM EDTA, 1.6 mM cysteine, 0.8 mM cystine at
pH 8 at 4°C under a N2-atmosphere for 25 h. The folded peptide was purified using a preparative
Vydac C18 column (47 × 300 mm, 15-20 µm, flow rate 40 ml/min; solvent A, 0.07% TFA;
solvent B, 0.07% TFA in acetonitrile/H2O 80:20; UV detection at 215 nm; with a gradient of 30-
55% B in 50 min). The relative molecular masses (Mr) were determined by ESMS
(Sciex API III, Perkin-Elmer): hBD27 (folded): 4751.3 (Mr calc. 4750.5), hBD23 (linear):
4523.9 (Mr calc. 4523.3), hBD29 (linear): 4249.6 (Mr calc. 4250.1). hBD4 (folded) 4367.1 (Mr
calc. 4366.1).
2.6.2 Assignment of the disulfide pattern of hBD27
The disulfide pattern of hBD27 was determined by two independent methods. Proteolytic
digestion with thermolysin and identification of the obtained fragments by mass spectrometry
and stepwise Edman degradation revealed a disulfide bond between Cys2 and Cys4. A fragment,
containing Cys1, Cys3, Cys5 and Cys6, was identified, but it could not be decided whether Cys1
is connected to Cys5 or Cys6 (and, respectively, Cys3 to Cys6 or Cys5). In another approach,
hBD27 was partially reduced using an established method (GRAY et al., 1993). The free thiol
groups of the partially reduced hBD27 were alkylated and the amino acid sequence of the
product was determined by automated Edman degradation. The result allowed the assignment of
disulfide bond Cys3-Cys6. Thus, synthetic hBD27 shows the disulfide pattern Cys1-Cys5, Cys2-
Cys4, Cys3-Cys6, which is identical to the pattern predicted for β-defensins (TANG et al., 1993).
2.6.3 Assignment of the disulfide pattern of hBD4
In order to determine the disulfide pattern of synthetic hBD4, a sample of the peptide was
subjected to proteolytic digestion with trypsin (modified, sequencing grade, Boehringer
Mannheim, Germany) and chymotrypsin (sequencing grade, Boehringer Mannheim, Germany)
at 36°C for 4 h. The combination of these two proteases allows cleavage of the peptide backbone
between the cysteine residues. This method is well established and widely used in the assigment
of disulfide patterns. The fragments, which were obtained from the digestion of hBD4, were
separated by HPLC and the collected fractions were first analyzed by electrospray mass
spectometry. The fractions which correspond to fragments containing cysteine residues were
subjected to automated Edman degradation on a 494 protein sequencer (ABI) in order to confirm
the amino acid sequence. Thus, two fragments could be identified, the first containing the
fragment Cys4-Pro-Asn-Thr-Tyr, connected to a fragment Cys-Arg, the second containing the
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three fragments Cys1-Ile-Gly Tyr, Cys-Arg and Ala-Cys5-Cys6-Leu-Arg. This analysis left two
questions open: the origin of the Cys-Arg fragments (one of them containing Cys2, the other
Cys3) and the connectivity of the two adjacent cysteine residues. In order to solve this problem,
another proteolytic digestion was performed with the combination of endoproteinase Arg-C and
chymotrypsin (both sequencing grade, Boehringer Mannheim, Germany) at 36°C for 5 h. The
digestion products obtained were separated and identified as described above. One fraction
contained the fragments Glu-Leu-Asp-Arg-Ile-Cys1-Gly-Tyr, Cys3-Arg-Ser-Gln-Glu-Tyr and
Ala-Cys5-Cys6-Leu, confirming the connection of Cys1 and Cys3 to Cys5/Cys6. Furthermore,
the Edman degradation of this peptide gave the possibility to solve the second problem,
concerning the disulfide connectivity of the two adjacent cysteine residues, since it allows the
Cys-Cys peptide bond to be cleaved, which is not possible by proteolytic digestion. The Pth-
derivates of cysteine, which are products of every degradation cycle, are analyzed by HPLC.
Derivates of cysteine, which appear after the second cysteine of a disulfide bridge has cleaved,
could be detected in the third and sixth degradation cycle, respectively. The cysteine in the third
cycle could generate only from the cysteines Cys3 and Cys6. Thus, the entire disulfide array is as
follows: Cys1-Cys5, Cys2-Cys4, Cys3-Cys6. This is in full agreement with the disulfide pattern,
which is published for the bovine BNBD-12 and which is regarded to be characteristic for β-
defensins.
2.7 Monoclonal antibody production
Monoclonal, hBD-4-specific antibodies were generated by Dr. Aleksandra Heitland. Mice were
immunized five times for a period of 17 days (short-term immunization: day 1, 4, 7, 14, and 17)
with coupled hBD4. For the immunization process, 200 µg antigen were required for one mouse
(10 animals were used for immunization, because the immune response depends on the
interindividual variability). Low molecular weight peptides (e.g. defensins) are not usually
immunogenic. The immunogenicity was enhanced by gentle polymerization with a carrier of
proteins (hemocyanin). The antigen was covalently bound to carbodiimide via the N-terminus.
The chemical coupling provides a better immunological response of the IgG-carbodiimide
complexes. Subsequently, popliteal lymph nodes of the immunized mice were fused (NIEBUHR et
al., 1998) with X63-Ag8.653 tumor cells. Thereby, spleen cells from an immunized mouse are
fused with mutated myeloma cells lacking the enzyme HPRT. Cells were grown in a medium
containing hypoxanthine, aminopterin and thymidine (HAT). Unfused myeloma cells cannot
grow in this medium because aminopterin blocks the purine synthesis. B cells die in this medium
even though they contain an enzyme (HPRT) that would allow them to utilize the hypoxanthine
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placed in the medium. The fused cells (hybridomas) grow and divide. The supernatant of wells in
which the hybridomas grow are screened by direct ELISA for the presence of reactive
monoclonal antibodies. The hybridomas producing this antibody are grown and frozen (YELTON
and SCHARFF, 1980). The selectivity of the resulted antibodies were tested by Western blot. The
antibodies were used during the immunohistochemical studies.
2.8 Characterization of antibodies by Western blot
To test the selectivity and sensitivity of the antibodies used in immunohistochemistry, Western
blot was performed under reducing conditions. Prior to the electrophoresis, a denaturation of the
samples and a prestained protein marker, Mark 12 Unstained Standard (Invitrogen), was
performed at 70°C for 10 min.
Samples were applied to the gel which was incorporated into an equipment XCell Sure Lock gel
chamber (Invitrogen). To obtain the sharpest bands, NuPAGE reducing agent, 0.5 M DTT in
stabilized liquid form (Invitrogen), was added just prior to heating and loading the samples.
Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) (NP0323, Invitrogen) with a
separation range of 2.5-200 kDa was used to achieve the separation. Denaturing running buffer,
2-N-morpholinoethanesulfonic acid NuPAGE MES SDS (Invitrogen), filled the inner chamber
and partially the outer one. Then, 500 µl of reducing agent NuPAGE (NP0005, Invitrogen) were
added to the running buffer in the inner chamber. This ensured that the reduced samples did not
reoxidize during electrophoresis. This undesirable effect could result in band broadening or band
splitting while the proteins migrate down the gel. The electrophoresis was performed at 200 V
for 35 min.. Subsequently, the electrophorized NuPAGE gels were removed, washed, and
prepared for a further blotting process which was performed using a transference chamber XCell
II Blot Module (Invitrogen). The PVDF transfer membrane (0.2 µM pore size, NEN), and filter
paper were embedded in methanol and transfer buffer respectively for an efficient transfer. The
transfer system was set up by assembling the blotting pads and gel-membrane sandwich
horizontally in the cathode (-) core of the blot module in the same sequence, so that the gel was
closest to the cathode plate. After adding enough presoaked blotting pads to rise to 0.5 cm over
the rim of the cathode core, anode (+) core was placed on the top of the pads. The blot module
was filled with transfer buffer until the gel-membrane sandwich was covered. The transference
was performed at 30 V for 60 min.
Running buffer:
50 ml 20 × NuPAGE running buffer (NP0002)
950 ml ddH2O
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Transfer buffer:
50 ml 20 × NuPAGE transfer buffer (NP0006-1)
1 ml NuPAGE Antioxidants
200 ml Methanol
749 ml ddH2O
After transference, the membrane was washed three times using TBS-T. The membrane was
blocked with 1 × Roti-Block (Roth) at room temperature for 1 h, to avoid non-specific binding
sites. Membrane was incubated with 4.5 ml of anti-hBD4 antibody and 500 µl of 10 × Roti-
Block (Roth) at 4°C, overnight. Afterwards, the membrane was washed three times with TBS-T.
Subsequently, the membrane was incubated with secondary antibody (anti-mouse-IgG
peroxidase conjugate) (Sigma, A9917), diluted 1:50.000 in 1 × Roti-Block at room temperature
for 1 h and shaken at 1.500 rpm. The membrane was washed 5 times with TBS-T. The signal
was developed using SuperSignal West Dura, Extended Duration Substrate (Pierce). This
product is a sensitive enhanced chemiluminescent substrate for detecting horseradish peroxidase
(HRP) on immunoblots. Signal was detected using the photographic method. Thus, CL-XPosure
film (Pierce) was exposed for 5 min and developed using Agfa Rodinal (1:25). The reaction was
stopped and results were fixed using Agfa Tetenal Superfix I (1:7). Membrane with the
corresponding peptides was stained with Indian ink to determine equal sample loading.
10 × TBS (Tris-saline buffer):
24.2 g Tris
80.0 g NaCl
The pH value of the solution was adjusted to pH 7.6 with approximately 20 ml  of 25%HCl, and afterwards filled up
with ddH2O until 1000 ml.
1 × TBS-Tween:
100 ml 10 × TBS
0.5 ml Tween 20
900 ml ddH2O
Indian ink solution:
50 ml TBS-T
0.15 ml Fount Indian ink (Pelikan)
2.8.1 Study of selectivity of monoclonal antibodies
An analysis of the crossreactivity was performed. For every synthetic peptide, (hBD1, hBD2,
hBD3, hBD4) 100 ng/µl were applied to a denaturing polyacrylamide gel. After blotting, an anti-
hBD4 monoclonal antibody was applied on a membrane containing the mentioned electroblotted
Material and methods                                                                                                                                              53
peptides. Subsequently, the results of the blotting process were developed as previously
described.
Antibodies included in this study: L1310D1; L1310D2; L1310G5; L1310G6; L1310H10; L1310A12; L11135aD12.
2.8.2 Study of sensitivity of monoclonal antibodies
To study the sensitivity of the antibodies, serial concentrations (3 ng, 30 ng, 100 ng, 300 ng) of
hBD4 (cyclic form) were applied to an electrophoresis gel (SDS-PAGE) (NP0323, Invtrogen).
Anti-hBD4 monoclonal antibody was applied to the membrane containing the synthetic peptide.
Subsequently, the results of the blotting process were developed as previously described (see
2.8).
2.9 Immunohistochemistry
Immunohistochemistry is a technique that detects antigens in tissue sections and cells by lectins,
monospecific monoclonal or polyclonal antibodies. In the present work, immunohistochemistry
was based on the use of enzyme-linked antibodies to detect tissue antigens. The substrate is
converted by the enzyme into a colored product that precipitates on the slide at the site of the
reaction (CHILDS and UNABIA, 1982).
2.9.1 Tissue preparation
The tissue used in immunohistochemistry was the tissue previously used for in situ hybridization
(see 2.5.1).
2.9.2 Preparation of paraffin sections
Sections were cut (5 µm) using a microtome (Microm HM340. Heidelberg, Germany) and
spread on slides (SuperFrost Plus, Menzel-Glaeser, Germany). Afterwards, they were
deparaffined using Rothistol (Roth). Slides were rehydrated 3 times for 7 min (Table 13).
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Table 13. Solutions and conditions used during the rehydration process.
Solution Condition
96% EtOH 2 min, twice
90% EtOH 2 min
80% EtOH 2 min
70% EtOH 2 min
50% EtOH 2 min
ddH2O 3 min
PBS 3 min
An antigen retrieval process was then performed on the sections. Thus, 4.7 ml of unmasking
solution (Vector Laboratories) were diluted in water to a final volume of 500 ml. Sections were
boiled for 3 min, and chilled to 30ºC. This step was repeated twice. Subsequently, sections were
washed in PBS for 8 min. Endogenous peroxidases may generate an intrinsic and non-specific
signal. These enzymes were inactivated by 3% H2O2, for 15 min. Slices were washed in PBS-T
(0.2% Tween 20) twice for 4 min. Sections were treated with blocking solution (PBS-T+ 10%
FCS) for 1 h to avoid non-specific bindings of the first antibody. Slides were incubated with
primary undiluted supernatant (containing anti-hBD4 monoclonal antibody), at 4ºC, overnight.
Endothelin-1 (ET-1) was used as positive control. ET-1 monoclonal antibody (Oncogenes, CN
Biosciences (UK) LTD, cat No. CP44-100) was used to identify the antigen. Then, sections were
washed in PBS-T, three times for 5 min. A biotinylated secondary antimouse antibody was used
to detect the primary antibody. One drop (±50 µl) of this biotinylated secondary antibody
(Vectastain ABC kit Elite, Mouse IgG, Vector Laboratories) was diluted in 2.5 ml of PBS-T.
This solution was supplemented with one drop (±50 µl) of normal serum. Slices were washed for
5 min. Preparations were incubated with ABC vectastain reagent (avidin biotinylated horseradish
peroxidase macromolecular complex), for 30 min at room temperature. Therefore, the binding
complex was amplified by adding this preformed molecule. Avidin is a glycoprotein with a high
affinity for the small molecular weight vitamin, biotin. The binding of avidin to biotin is
essentially irreversible. To remove the excess of these macromolecular complexes, sections were
then washed with PBS-T, twice for 2 min. The signal was developed by adding staining solution
for 3 min:
1 ml PBS
one tablet urea-H2O2, Sigma fast
one tablet 3.3´diaminobenzidine, Sigma fast
Slices were mounted using Mowiol solution (48 g Mowiol 488 [Sigma-Aldrich, Cat. 32.459-0]
in 21.1% glycerol/ 0.1 M Tris/HCl, pH 8.5).
Material and methods                                                                                                                                              55
2.10 Antimicrobial activity
2.10.1 Radial diffusion assay
Radial diffusion assay (LEHRER et al., 1991) is a fast and simple procedure for the examination
of antimicrobial activity in aqueous solutions. It consists of the measurement of the inhibition of
bacterial growth, surrounding an applied substance in feeding agar. Bacteria strains were grown
in 5 ml of growth medium at 37°C for 18 h, until they reached a OD600 = 0.8 (see 2.4.1).
Subsequently, 500 µl of the bacteria were diluted in 100 ml of the suitable medium (see 2.4.1).
Then, 25 ml medium were placed into sterile Petri dishes, which were stored at 4°C. With the
help of a sterile hollow needle, small holes were punched (3 mm in diameter) and removed from
the gel. The peptides were applied in these cavities in different concentrations (2 µg, 10 µg,
20 µg). The agarose plates were then incubated at 37°C for 18 h. The positive controls, 10 µg of
doxycycline, vancomycin, and MBI 28 were applied in cavities on the same plates. The diameter
of the inhibition zone around the wells was measured using the metric scale (0.1 mm
increments). The diameter of clearing was expressed in units (0.1 mm=1 U) and was calculated
by subtraction of the well diameter (3 mm = 30 U).
0.03% Tryptic Soy Broth (Sigma T-8261)
0.80% NuSieve GTG Agarose (Biozym)
0.02% Tween 20
10 mM Natriumphosphate buffer, pH 7.2
2.10.2 Minimal inhibitory concentration (MIC)
The minimal inhibitory concentration (MIC) is the lowest concentration (µg/ml) of an antibiotic
that inhibits bacterial growth under standard conditions. The MIC for a bacterial population is
determined by a serial dilution test (SÜßMUTH et al., 1999). MIC and the agar diffusion test (see
2.10.1) are optimal methods to evaluate the antimicrobial activity. Series of test tubes were filled
with different concentrations of a particular antibiotic. Serial dilutions of peptides (factor 0.5) were
prepared in test medium, TSB in 10 mM sodium phosphate buffer (pH 7.2). First of all, 100 µl of a
defined concentration of peptide was applied in test medium in the superior cavity, while all other
recesses were filled by adding 50 µl pure test medium. Starting at the superior cavity, 50 µl solution
containing peptide were transferred to the underlying cavities in each case, mixed and this solution
of bisected concentration was transferred again to a cavity below. Bacteria grew for 18 ± 2 h and
then a standard inoculum of 50 µl bacterial suspension in test medium containing
2 × 105 to 5 × 105 CFU/ml was added to each test tube with 50 µl of the prepared peptide solution.
After incubation at 37°C for 16 to 20 h, bacterial growth was determined by visual analysis and
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absorbance measurement at 570 nm using a Dynatech microplate reader. Since the number of added
cells has a direct influence on the MIC value, the dilution of the overnight culture of bacteria has to
be determined previously.
The dilution level went from 1:2000 to 1:10.000 according to the NCCLS guidelines (ISENBERG et
al., 1993). The germ density determined experimentally was the result of a 1:10000 dilution from
the original culture. The optimal number of bacteria in this dilution is 2-5 × 105. A further 1:1000
dilution was performed and 100 µl were spread onto an agar plate. The plate was incubated
overnight. Then, colonies were counted and the value was multiplied by 10.000 in order to know the
number of bacteria per milliliter of a 1:10000 dilution.
2.11 Hemolysis studies
The investigation of the hemolytic activity of the new human β-defensins was achieved according to
the studies of HELMERHORST et al., 1999. Erythrocytes from collected full blood from healthy
young donors was stored in citrate-buffered (Monovetten, Sarstedt). Blood was then centrifuged at
1500 × g for 10 min and the supernatants removed with a Pasteur pipette. The erythrocyte-rich
pellet was washed, resuspended in one volume of test medium (1/10 TSB, 287 mM glucose,
PH 7.4), and centrifuged as previously. The isotonic glucose concentration was used to prevent a
nonspecific hemolysis in the hypotonic environment (osmoprotection). Erythrocytes were diluted
with test medium to a final volume of 200 µl. On the other hand, different concentrations of hBD23
and hBD27 (1-250 µg/ml) were pipetted and lyophilized into a 96-well-micro V bottom plate. The
erythrocyte solution was added to the wells containing different concentrations of hBD23 or hBD27
and incubated at 37°C for 1 h. The 96-well-micro V bottom plates were centrifuged afterwards at
1000 × g for 5 min. Then, 150 µl of supernatant per cavity was transferred into a new 96-well-micro
V bottom plate with a flat botton. The solution was colored by free hemoglobin and the
concentration determined by measurement at λ = 450 nm in a microplate reader (BIO-Tech
Instruments). The incubation with different concentrations of MBI-28 (GOUGH et al., 1996) was
used as reference for the hemolytic activity. Erythrocytes were incubated with test medium which
was used as negative control.
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The hemolytic activity of hBD-4 was calculated according to the following formula:
Hemolysis [%] =
Ø A450nm (hBDX) Ø- A450nm (Negative  control)
A450nmØ (1% Tween 20) - A 450nmØ (Negative control)
x100
2.12 Data bank and software
The comparison of different sequences of DNA fragments as well as the translation of these
nucleotide sequences into an amino acid sequence were achieved with the Sequencer V3.1
software (ABI).
The search for public and accessible sequence information (e.g. EST clones, genomic contigs)
was performed in Internet data bases: NCBI (National Centers for Biotechnology Information)
and its algorithm basic local alignment search tool (BLAST, ALTSCHUL et al., 1997). The
program signalP V2.0 was used for the investigation of putative signal peptide sequences
(NIELSEN et al., 1997). This thesis was created with programs of the Microsoft Office package.
The graphics, including media and standard deviations (SD), represented in the results section,
were calculated with GraphPad Prism 3.0.
2.13 Discovery of new β-defensin genes in silico
Biosciences are progressively dependent on information technology and comprise a huge amount of
complex data. Genes and DNA have attracted most attention, since DNA sequencing techniques
have allowed genome sequencing projects to be a reality. Since the beginning of the systematic
human genome analysis, a great deal of effort has been made to identify new genes by using
bioinformatical approaches. During the present work several bioinformatical programs were used.
BLAST (Basic Local Alignment Search Tool) is a set of similarity search programs designed to
explore all of the available sequence databases regardless of whether the query is protein or
DNA.
ORF Finder (Open Reading Frame Finder) is a graphic analysis tool which is designed to find all
open reading frames of a selectable minimum size in a user's sequence or in a sequence already
in the database. This tool identifies open reading frames using the standard or alternative genetic
codes. The deduced amino acid sequence can be saved in various formats and searched against
the sequence database using the BLAST server.
PATTINPROT is a tool to scan a protein database of one or several sequences for one or several
patterns.
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Figure 11. Strategy for the identification of new β-
defensin genes.
The discovery of these new genes was based on the
use of bioinformatical approaches described in the
diagram.
Search of first exon by bioinformatical approach
         by PCR and sequencing process
and further confirmation of nucleotide sequence
Copy the cleaned sequences in the ORF Finder
 (http://www.ncbi.nlm.nih.gov/gorf/gorf.html)
Translation of nucleotide sequence into six open reading frames
Copy the individual amino acid sequences in PATTINPROT
automatic search of defensin-consensus-sequence
C-x(5,7)-C-x(3,4)-C-x(6,8)-G-x-C-x(5,7)-CC
 (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_pattinprot.html)
Translation into the nucleotide sequence
(EICRNLEGRCRKKCLENEVQIGLCSNRLKCCL)
Standard protein-protein Blast
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi)
Consensus fragment assembled with the sequence AA298819
The alignment of well known ß-defensins
(http://www.ncbi.nlm.nih.gov/blast/)
included in public domain tool ( Blast)
The correspondent EST shared significant similarities
of chromosome 20 (AL360078,  AL121751)
resulted in a consensus sequence
To remove all the digits and marks in sequences
contigs were processed by a bioinformatical cleaner
 (http://www.mbshortcuts.com/cleaner/index.htm)
with sequences encoded in gemonic contigs
Discovery of hBD23, 27, 29 amino acid sequences
(codified by second exon)
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3. Results
3.1 Identification of full-length β-defensin cDNAs
The identification and description of three new genes was based on the fundamentals of
functional genomics. The systematic search for new human β-defensin genes as previously
described (Figure 11) led to the identification of three new genes. The alignment of known β-
defensin amino acid sequences mapping on chromosome 8 (hBD1 to hBD4) resulted in a
consensus sequence (EICRNLEGRCRKKCLENEVQIGLCSNRLKCCL), which was included in
a public domain tool (BLAST). This bioinformatical approach assembled the consensus
fragment with a sequence (AA298819) whose corresponding EST sequence shared significant
similarities to sequences located on two genomic contigs, at the telomere (AL360078) and
centromere (AL121751) of chromosome 20. The complete sequences were translated into six
open reading frames. The different frames were translated into the amino acid sequence and
analyzed for the occurrence of the β-defensin-specific cysteine pattern using PATTINPROT
(http://npsa-pbil.ibcp.fr). The well known cysteine pattern for human β-defensins was found in
three sequences. Thereby, three new members of this family of cationic peptides were identified
(DEFB23, DEFB27, and DEFB29). After deducing the putative second exon of the genes, their
full-length cDNAs were investigated. For this purpose the research was performed as follows:
1-Search by computer of the putative first exon: upstream sequences from the second exon were
translated in silico into three frames. Then, the sequences were analyzed using SignalP server
(http://www.cbs.dtu.dk/services/SignalP-2.0/) to identify their putative signal peptides.
2-For each candidate sequence (deduced previously in silico), reverse primers from the second
exon and forward primers upstream of a putative ATG start codon were designed and tested for
amplification. Using human testis cDNA as a template, specific products were detected,
subsequently cloned into pGEM-T vector (Promega) and sequenced. In addition, during the
bioinformatical analysis of chromosome 20, two putative genes were found (DEFB16 and
DEFB22). These sequences were not considered as real genes due to the following reasons:
An iterative blast search was performed against the human databases to identify additional
related sequences and a search for EST sequences that would confirm the transcription of the
sequences. However, no evidence was found.
To confirm whether or not these sequences are expressed, RACE-PCR was accomplished under
different conditions and several tissues (testis, skeletal muscle, liver, lung) were tested for the
occurrence of the two genes. These experiments gave no amplification product, leading to the
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conclusion that previous exons with the corresponding start codons do not exist for these
sequences.
3.2 Structure of DEFB23, DEFB27, and DEFB29 genes
The analysis of the genomic structure revealed that all newly identified sequences consist of only
two exons and one intron. After the translation of DNA to RNA, this molecule needs to be
matured by elimination of the intron during the splicing process.
Exon 1 Exon 2
Intron
AAA
5-UTR 3-ÚTR
mRNA
Predicted signal peptide  β-defensin cysteine pattern:
C-x(5,7)-C-x(3,4)-C-x(6,8)-G-x-C-x(5,7)-CC
Figure 12. Schematic representation of the common genomic structure of DEFB23, DEFB27 and DEFB29
genes.
The genes consist of two exons separated by the intron. The intron is subsequently eliminated during the maturation
of RNA. Untranslated regions (UTR) at the 5´and 3´ends as well as the poly-A tail are also indicated. The predicted
signal peptide is encoded by the first exon and the β-defensin cysteine pattern by the second exon.
This genomic structure was also shared by DEFB1, DEFB2, DEFB3, DEFB4, and DEFB6
whereas DEFB5 exhibited 3 exons (YAMAGUCHI et al., 2002). The analysis showed that a
predicted signal peptide is encoded by a first exon and the cysteine-containing core structure
which is indicative of the β-defensin family is encoded by the second exon. Further PCR analysis
and in silico EST search provided no indication of additional exons or splicing variants for any
of the novel cDNAs. After the study of the sequences in silico and further confirmation in the
laboratory, more details were revealed about the composition of these three new genes, as shown
in the following figures (Figure 13, Figure 14, Figure 15). The signal peptide is also depicted,
indicating the putative position for the cleavage site of the amino acid sequences that would
result in the mature peptide.
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gcagcttcattttgggctgccttagcc ATG  AAG  CTC  CTT  TTG  CTG  ACT  TTG  ACT  GTG  CTG  CTG  
 M       K        L L L L        T        L       T        V       L L
CTC  TTA  TCC  CAG  CTG  ACT  CCA  GGT  GGC  ACC  CAA  AGA  TGC  TGG  AAT  CTT  TAT  GGC  AAA  TGC  CGT  TAC  
    L        L       S       Q        L        T       P        G        G       T        Q        R       C        W       N        L      Y       G        K        C        R       Y
AGA  TGC  TCC  AAG AAG  GAA  AGA  GTC  TAT  GTT  TAC  TGC  ATA  AAT AAT  AAA  ATG  TGC TGC  GTG  AAG  CCC
  R       C         S        K       K        E         R       V       Y       V       Y       C        I        N        N        K       M       C       C         V        K       P
AAG  TAC  CAG  CCA  AAA  GAA  AGG  TGG TGG  CCA  TTT taactgctttgaagcctgaagccatgaaaatgcagatgaagctcccagtgg
   K       Y        Q       P        K        E        R       W W       P        F      .
attcccacactctatcaataaa
hBD23  R TM
hDB23 F in situ hBD23  F TM
Intron (9320 bp)
hDB23 R in situ
23 Probe TMhBD23  F TM
63
12
129
34
195
56
279
67
301
Figure 13. Structure of the hBD23 gene.
The translated amino acid sequence is positioned under the cDNA sequence. Capital letters correspond to the
translated region. The cDNA encoding the putative signal peptide is underlined. The intron is labeled by a vertical
arrow separating exon 1 and exon 2. The characteristic six cysteines of β-defensins are labeled with bold letters.
Position and orientation of all oligonucleotides used for cloning, study of expression, and regulation analysis are
indicated by horizontal arrows.
gtgcagttcactggaccaaaagctttggctgcacctcttctggaaagctggccat
ggggtcttc  ATG  ATC  ATT  GCA  ATT  CTG CTG  TTC  CAG  AAA  CCC  ACA  GTA   ACC   GAA  CAA  CTT  AAG
                               M         I        I        A         I        L         L       F         Q        K         P         T        V         T        E         Q         L        K
AAG  TGC  TGG  AAT  AAC  TAT  GTA  CAA  GGA  CAT  TGC  AGG  AAA  ATC  TGC  AGA  GTA  AAT  GAA  GTG  CCT
GAG  GCA  CTA  TGT  GAA  AAT  GGG  AGA  TAC  TGT  TGC  CTC  AAT  ATC  AAG  GAA  CTG  GAA  GCA  TGT  AAA
  E        A         L        C         E        N        G         R         Y         C        C        L        N         I        K        E         L        E        A        C        K 
AAA  AT T  ACA  AAG  CCA  CCT  CGT  CCA  AAG  CCA  GCA  ACA  CTT  GCA  CTG  ACT  CTT  CAA  GAC  TAT  GTT
   K         I         T         K        P P      R         P         K        P         A         T         L       A         L        T         L       Q         D        Y        V
ACA  ATA ATA  GAA  AAT  TTC  CCA  AGC  CTG  AAG  ACA  CAG  TCT  ACA taaatcaaatacaatttcgttttcac
   T         I I        E         N        F         P         S         L         K         T        Q         S        T       .
ttgcttctcaacctagtctaataaactaaggtgatgagatatacatcttcttccttctggtttcttgatccttaaaatgaccttcgagcatatt
 DEFB27 R  in situ  
DEFB27 F in situ DEFB27 F TM
DEFB27  F  TM
DEFB27 Probe TM
Intron (1180 bp)
DEFB27  R  TM
55
118
18
181
   K        C        W        N        N         Y        V        Q         G        H        C        R        K         I         C       R         V       N        E         V         P 39
244
60
81
375
95
469
307
Figure 14. Structure of the hBD27 gene.
The translated amino acid sequence is positioned under the cDNA sequence. Capital letters correspond to the
translated region. The cDNA encoding the putative signal peptide is underlined. The intron is labeled by a vertical
arrow separating exon 1 and exon 2. The characteristic six cysteines of β-defensins are labeled with bold letters.
Position and orientation of all oligonucleotides used for cloning, study of expression, and regulation analysis are
indicated by horizontal arrows. The gene was registered in Gene Bank with the accession number AF525929.
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cactgtttgagcacctaaaaaaa
caacc  ATG  AAG  CTC  CTT  TTT  CCT  ATC  TTT  GCC  AGC  CTC  ATG  CTA  CAG  TAC  CAG  GTG  AAC  ACA GAA  TTT 
                M        K       L  L       F       P        I        F       A        S        L       M       L        Q       Y        Q       V       N        T        E       F
ATT  GGC  TTG  AGA  CGC  TGT  TTA  ATG  GGT  TTG  GGG  AGA  TGC  AGG  GAT  CAC  TGC  AAT  GTG  GAT  GAA  AAA
      I       G        L        R       R        C        L       M       G       L        G        R       C         R       D        H       C       N       V       D        E        K
GAG  ATA  CAG  AAA  TGC  AAG  ATG  AAA  AAA  TGT  TGT  GTT  GGA  CCA  AAA  GTG  GTT  AAA  TTG  ATT  AAA  AAC
  E          I        Q       K        C        K        M       K        K       C      C     V       G        P        K        V       V        K       L        I        K        N
TAC  CTA  CAA  TAT  GGA  ACA  CCA  AAT  GTA  CTT  AAT  GAA  GAC  GTC  CAA  GAA  ATG  CTA  AAA  CCT  GCC  AAG
   Y       L       Q        Y       G        T        P       N       V        L        N       E         D       V       Q        E        M       L        K        P      A        K
AAT  TCT  AGT  GCT  GTG  ATA  CAA  AGA  AAA  CAT  ATT  TTA  TCT  GTT  CTC  CCC  CAA  ATC  AAA  AGC  ACT  AGC  TTT
   N       S        S        A       V        I        Q        R        K        H        I       L       S       V       L        P        Q        I        K        S        T        S       F
TTT  GCT  AAT  ACC  AAC  TTT  GTC  ATC  ATT  CCA  AAT  GCC  ACC  CCT  ATG  AAC  TCT  GCC  ACC  ATC  AGC  ACT  ATG
F      A       N       T       N        F        V        I        I        P        N        A        T       P       M       N        S       A        T        I        S       T       M
ACC  CCA  GGA  CAG  ATC  ACA  TAC  ACT  GCT  ACT  TCT  ACC  AAG  AGT  AAC  ACC  AAA  GAA  AGC  AGA  GAT  TCT  GCC
T       P        G       Q         I         T       Y       T        A        T       S       T       K        S        N        T         K       E        S        R        D       S       A
ACT  GCC  TCG  CCA  CCA CCA  GCA  CCA  CCT  CCA  CCA  AAC  ATA  CTG  CCA  ACA  CCA  TCA  CTG  GAG  CTA  GAG  GAA
    T       A        S        P        P       P       A         P        P        P       P       N        I         L       P        T        P         S        L       E        L       E        E
GCA  GAA  GAG  CAG taatgtggatctttcccttaaaactccaagttcctctctatttttgctatctataaaatgacatagaactgtttcctctgtcatcagtcattcaataaa
   A        E        E       Q    .
DEFB29 F in situ Intron  (1931 bp)
DEFB29 F TM
DEFB29 R in situ
DEFB29 Probe TM
DEFB29 Probe TM DEFB29 R TM
68
134
43
266
110
404
181
21
200
65
87
335
133
473
156
542
179
278
301
Figure 15. Structure of hBD29 gene.
The translated amino acid sequence is positioned under the cDNA sequence. Capital letters correspond to the
translated region. The cDNA encoding the putative signal peptide is underlined. The intron is labeled by a vertical
arrow separating exon 1 and exon 2. The characteristic six cysteines of β-defensins are labeled with bold letters.
Position and orientation of all oligonucleotides used for cloning, study of expression, and regulation analysis are
indicated by horizontal arrows. The gene was registered in Gene Bank with the accession number AF525931.
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3.3 Comparison of exon-intron boundary region
The corresponding exon-intron boundaries were assessed by alignment of the cDNAs with the
genomic contig. Conserved splicing sequences were detected inside exon 1, exon 2, and the
intron within the regions close to the exon-intron boundaries.
                                   Exon 1                                                     Intron                                                  Exon 2
DEFB23 TTATCCCAGCTGACTCCAG –gtaacctg (9320bp) tgtgt-cag- GTGGCACCCAAAG
DEFB27 CTGTTCCAGAAACCCACAG -gtaaaccg (1180bp) tgtgtatag- AACCGAACAACTT
DEFB29 CAGTACCAGGTGAACACAG –gtaatgtg (1931bp) tat—-acag- AATTTATTGGCTT
Figure 16. Comparative study of the exon-intron boundary region for DEFB23, DEFB27, and DEFB29.
The numbers in parentheses indicate the length of the introns. Short but conserved sequences for the three new
genes were detected and marked in black and those conserved in only two genes are labeled in grey.
3.4 Chromosomal location
Defensins described so far (DEFB1, DEFB2, DEFB3, DEFB4, DEFB5, and DEFB6) have been
located on chromosome 8p23. In contrast, the three new defensins described in the present work
are mapping on chromosome 20, separated in two different clusters: DEFB23 on the centromere
of chromosome 20 (20q11.1), whereas DEFB27 and DEFB29 on the telomere of this
chromosome (20p13).
Chromosome 20Chromosome 8
Chromosomal location
of  DEFB27 and DEFB29
Chromosomal location
of DEFB23
Chromosomal location
of DEFB1, DEFB2, hBD3,
DEFB4, DEFB5, and DEFB6.
DEFB22
DEFB16
DEFB29
DEFB27
DEFB23
Figure 17. Chromosomal location for β-defensin genes.
Mapping regions and the orientation of the new genes on chromosome 20 are indicated (black arrow). The
pseudogenes DEFB16 and DEFB22 are also depicted (open arrow).
During the analysis of chromosome 20, two candidate pseudogenes were found: DEFB16 and
DEFB22. These genes are located on chromosome 20q11.1 and positioned in the opposite
direction to the existing β-defensins.
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The analysis and comparison of the introns for eight β-defensins did not allow a direct
correlation between their length and the chromosomal location. Nevertheless, the difference
between the intron length of DEFB3 and DEFB23 was notable. DEFB5 was not included in the
table since this β-defensin exhibited two introns.
Table 14. Length of introns of β-defensins described to date.
                                                         Chromosome 8                                            Chromosome 20
DEFB1 DEFB2 DEFB3 DEFB4 DEFB6 DEFB23 DEFB27 DEFB29
Intron 6972 bp 1692 bp 943 bp 4495 bp 3575 bp 9320 bp 1180 bp 1931 bp
The length of hBD1 (6972 bp) was determined by alignment of the genomic DNA (accession
number AF205406) with the cDNA (accession number NM005218) by using the program
Pairwise Blast 2 sequences (http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html). This length
differed from the length proposed by Kaiser and Diamond (2000) that was reported to be 10 kb.
3.5 Comparison of amino acid sequences
Using the full-length cDNA as template, the deduced amino acid sequences were aligned in
conjunction with the sequences of known β-defensins and β-defensin-like proteins. A
comparison between amino acid sequences encoded by genes mapping on chromosome 8 and
those encoded on chromosome 20 was performed. According to the results obtained in silico
with the signal peptide program, the predicted signal peptide for β-defensins could be obtained.
The described exon for pseudogene DEFB16 coded for an amino acid sequence containing seven
cysteines, a property only shared by the confirmed DEFB5, DEFB6, and DEFB27 genes. The
additional cysteine of hBD16 and hBD5 was located in a position preceding the cysteine-
containing core, whereas for hBD6 and hBD27 it occurred behind the mentioned pattern.
Two common features, a conserved glycine between cysteines 1 and 2, as well as a glutamic acid
between cysteines 3 and 4 were observed. In contrast to the primary structure of the published
peptides hBD1 to hBD6, HE2C, HE2E (Chr. 8p23) and hBD23 (Chr. 20q11.1), longer carboxy-
terminal extensions following the cysteine-containing core were determined for hBD27 and
hBD29 (both on Chr. 20p13). The mentioned terminal fragments exhibited only minor sequence
similarities within themselves or any other known protein motif.
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         1........10........20........30...
hBD-1    MRTSYLLLFTLCLLLSEMASGGNFLTGLGHRSDH
hBD-2    MR-VLYLLFSFLFIFLMPLPGVFG-----GIGDP
hBD-3    MR-IHYLLFALLFLFLVPVPGHG----GIINTLQ
HE2E     MKVFFLFAVLFCLVQTNSG-------DVPPGIRN
HE2C     MRQRLLPSVTSLLLVALLFPGSSQA-(51)-LKV
hBD-4    MQ-RLVLLLAISLLLYQDLPVRS------EFELD       41
hBD-5    MALIRKTFYFLFAMFFILVQLPSGCQAGLDFSQPFPSGEFAVC
hBD-6    MRTFLFLFAVLFFLTPAKNA           FFD                     25
hBD-16                                   GLGGLDSVMFCFAVGLLVVIRREPW
hBD-22                           TLSGKEKGRI
hBD-23   MK-LLLLTLTVLLLLSQLTPG-----------GT
hBD-27   MG-----LFMIIAILLFQKPTVT------E--QL
hBD-29   MK----LLFPIFASLMLQYQVNT------EFIGL
         .....40........50........60........70........80........90........100.......110.........
hBD-1    YNCV--SSGGQCLYSACPIF-TK---IQ-GTCYRGKAKCC---------K-------------------------------------
hBD-2    VTCL--KSGAICHPVFCP----RRYK-QIGTCGLPGTKCC---------KKP-----------------------------------
hBD-3    KYCR-VRGG-RCAVLSCLPKEE-----QIGKCSTRGRKCC---------RRKK----------------------------------
HE2E     TICRMQQ--GICRLFFCHSGE-KKKDI----CSDPWNRCCVSNTDEEG-KEKPEMDGRSGI--------------------------
HE2C     VDCRR-SE-GFCQEY-CNYMET-----QVGYCSKKKDACCLH---------------------------------------------
hBD-4    RICG--YGTARCRKK-CRSQEYR-----IGRCPNTYA-CCL--------RKWDESLLNR----------------------------
hBD-5    ESCKLGRGK—-CRKE-CLENE-KPGDN----C-RNFL-CC---------RQRI----------------------------------
hBD-6   DEKCNKLKGT--CKNN-CGKNEE-LIAL----CQKSLK-CC---------RTIQPCGSIID---------------------------
hBD16    NPCELYQGM—-CRNA-CREYEYQY-LT----CPNDGK-CCLKLSVKITSSKNVKEDYDSNS--------------------------
hBD22    ETCWNFRGS—-CRDE-CLKNERVYVF-----CVSGKL-CCLKPKDQPHLPQHIKN--------------------------------
hBD-23   QRCWNLYGK—-CRYR-CSKKERVYV-----YCINNKM-CCV--------KPKYQPKERWWPF-------------------------
hBD-27   KKCWNNYVQGHCRKI-CRVNEVP-EAL----CENG-RYCCLNIKELEACKKITKPPRPKP---------------------------
hBD-29   RRCE--MGLGRCRDH-CNVDEK--E-IQ--KCKM--KKCCVGPKVV---KLIKNYLQYGTPNVLNEDVQEMLKPAKNSSAVIQRKHI
         ........130.......140.......150.......160.......170.......180.......190.......200......
hBD-1    ---------------------------------------------------------------------------------------
hBD-2    ---------------------------------------------------------------------------------------
hBD-3    ---------------------------------------------------------------------------------------
hBD-4    ---------------------------------------------------------------------------------------
hBD-5    ---------------------------------------------------------------------------------------
HE2E     ---------------------------------------------------------------------------------------
HE2C     ---------------------------------------------------------------------------------------
hBD16    ---------------------------------------------------------------------------------------
hBD22    ---------------------------------------------------------------------------------------
hBD-6    ---------------------------------------------------------------------------------------
hBD-23   ---------------------------------------------------------------------------------------
hBD-27   --------ATLALTLQDYVTIIENFPSLKTQST------------------------------------------------------
hBD-29   LSVLPQIKSTSFFANTNFVIIPNATPMNSATISTMTPGQITYTATSTKSKSNTKESRDSATASPPPAPPPPNILPTPSLELEEAEEQ
Figure 18. Multiple sequence alignment of putative human β-defensin peptides.
The predicted signal peptides are underlined. The conserved and additional cysteines are boxed. Acidic amino acids
are shaded in gray, whereas basic residues are printed inversely. The number in parentheses denotes additional
amino acids at the amino-terminus of HE2C. Pseudogenes are labeled in italics.
3.6 Endogenous expression of the new β-defensin genes in human tissues
The tissues were purchased from Clontech Laboratories (Palo Alto, CA. USA) or kindly
provided by Professor Dr. Markus Buechler (Heidelberg, Germany) and PD Dr. Helmut Friess
(Bern, Switzerland) (see 2.3.1). The mRNA abundance in 28 human tissues was quantified
including known places of β-defensin expression.
After the isolation of mRNA, a standard procedure of reverse transcription was carried out (see
2.3.3). cDNA was produced from each tissue and used for the determination of expression of
each new gene.
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Following the cloning, a systematic approach for the evaluation of the relative transcript level in
28 human tissues was performed by real-time quantitative RT-PCR (TaqMan) (see 2.3.4). Using
the Primer-Express Software (Perkin-Elmer), specific forward primers (TM.F), reverse primers
(TM.R), and double-labeled TaqMan probes (TM.P) were deduced for DEFB23, DEFB27,
DEFB29.
The length of the resulting amplicons was designed to be between 87 and 115 bp. The amplicons
are shorter than the full-length cDNA in order to reduce the possibility that the enzyme leaves
the synthesis during the extension process before reaching the position of the reporter.
In order to increase specificity, only amplicons spanning the exon-intron boundary of the
corresponding β-defensin gene were chosen. Therefore, a highly comparable efficiency of
amplification was provided.
Serial dilutions of the cloned cDNAs were used to generate a standard curve. Amplifications of
all tissues were normalized to these standard curves leading to a relative copy number of the
corresponding DEFB transcripts.
For relative quantification, these data were normalized to glyceraldehyde-3-phosphate
dehydrogenase (hGAPDH) expression levels in each tissue tested. Experiments were performed
three times in duplicate. An absolute standard curve used as external calibration required that the
absolute quantities of the standard were known by some independent means. Plasmid DNA with
the insert of interest served as absolute standard and was used for sample interpolation. Thus,
calculations were performed applying a described mathematical formula (see 2.3.5). Using this
approach, the transcription level of the new β-defensins in different human tissues was
compared.
The amplification in some tissues was significant, but had a range of 1 to 25 transcripts in 7.5 ng
RNA-equivalent amount with a high standard deviation, therefore they were not included in the
following figures.
The study of DEFB23 expression showed a restricted pattern located in five tissues. The highest
expression of DEFB23 was found in the male reproductive tract. Constitutive expression was
also detected in skeletal muscle, trachea, heart and lung. The relative abundance of transcripts of
DEFB23 is much higher in testis and skeletal muscle than in trachea, heart and lung.
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Figure 19. Tissue distribution of DEFB23.
The expression pattern of DEFB23 was studied by real-time quantitative RT-PCR, (TaqMan) in 28 different human
tissues. The remaining tissues are not shown because some of them had a range of 1 to 25 transcripts in 7.5 ng RNA-
equivalent amount with a high standard deviation. The relative abundance was normalized to hGAPDH (+/-SD in
logarithmic scale). Experiments were carried out at least twice in duplicate.
The evaluation of the expression pattern of DEFB27 showed that this gene was expressed in
testis, kidney, pancreas, skeletal muscle, liver, and lung. DEFB27 had a more widespread
distribution in the human body. Consistent with the previously studied DEFB23, the highest
expression level was detected in the male reproductive organ.
Figure 20. Tissue distribution of DEFB27.
The expression pattern of DEFB27 was studied by real-time quantitative RT-PCR, (TaqMan) in 28 different human
tissues. The remaining tissues are not shown because some of them had a range of 1 to 25 transcripts in 7.5 ng RNA-
equivalent amount with a high standard deviation. The relative abundance was normalized to hGAPDH expression
(+/- SD in logarithmic scale). Experiments were performed at least twice in duplicate.
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Whereas other tissues like trachea (DEFB23; HONG et al., 2002; DIAMOND et al., 2000), or skin
(CHRONELL et al., 2001; BOS et al., 2001; HUH et al., 2002; ONG et al., 2002; MARCHINI et al.,
2002) show expression of known β-defensins, DEFB27 expression is completely absent in these
tissues.
The study of hBD29 expression in human tissues revealed a restricted distribution in the male
genital tract and skeletal muscle, showing an exclusive expression for these two tissues. No
detectable expression was found in any of the other tissues tested.
Figure 21. Tissue distribution of DEFB29.
The expression pattern of DEFB29 was studied by real-time quantitative RT-PCR, (TaqMan) in 28 different human
tissues. The remaining tissues are not shown because some of them had a range of 1 to 25 transcripts in 7.5 ng RNA-
equivalent amount with a high standard deviation. The relative abundance was normalized to hGAPDH (+/-SD in
logarithmic scale). Experiments were performed at least twice in duplicate.
A comparison of the expression for the three genes (DEFB23, DEFB27, and DEFB29) was
performed. The tissues that showed constitutive expression of the new β-defensin genes are
shown (Figure 22). DEFB27 was expressed in more tissues than the other two β-defensins. In
fact, DEFB29 was specifically expressed in two tissues, testis and skeletal muscle. In general,
both tissues had a high number of copies for the three genes. DEFB27 was expressed in liver,
pancreas and kidney, whereas the other two new β-defensin genes were not expressed. DEFB23
was expressed in trachea, a frequently infected tissue, but no transcripts were detected for
DEFB27 and DEFB29.
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Therefore, each defensin exhibited a distinct expression pattern. However, a common feature
seemed to be the high number of copies of the three new genes in testis and skeletal muscle.
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Figure 22. Comparison of tissue distribution for the novel DEFB23, DEFB27, and DEFB29 genes.
Tissue distribution of DEFB23, hBD27, and hBD29 studied by real-time quantitative RT-PCR (TaqMan). The
remaining tissues are not shown because some of them had a range of 1 to 25 transcripts in 7.5 ng RNA-equivalent
amount with a high standard deviation. Relative abundance was normalized to hGAPDH (+/-SD in logarithmic
scale). Experiments were performed at least twice in duplicate.
3.7 Regional distribution of the new β-defensin genes in human epididymis
Since the male genital tract exhibited the highest copy number, the interest became focused on
this organ. The local distribution of the three novel β-defensins in testis and epididymis was
studied in more detailed research. The expression of the previously described DEFB4, which
exhibited a comparable tissue distribution pattern, with the highest mRNA abundance in the
male genital organ (GARCIA et al., 2001-B; RODRIGUEZ-JIMENEZ et al., 2003) was also
evaluated. For this purpose, tissue samples were obtained from four different patients suffering
from testicular tumors. Tissues were kindly provided by Prof. Dr. C. Stief from the Urology
Department of Hannover Medical School (MHH, Hannover, Germany). The tissue was separated
into six functionally different parts (testis, rete testis, caput, corpus, the proximal and distal
segments of cauda epididymis). RNA was isolated to generate the corresponding cDNAs.
Significant interindividual differences in the expression pattern of the four patients were not
observed. An illustrative picture above each figure was added for better visualization of the
anatomical distribution (e.g. Figure 23, modified from the Sobotta Atlas of Anatomy, URBAN
and SCHWARZENBERG 1997).
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3.7.1 Study of DEFB23 expression along the male reproductive tract
The evaluation of the DEFB23 expression in different segments of human testis and epididymis,
showed than in general the highest level of expression was in testis. It is interesting to note that
the transcription level decreased from testis to rete testis, but increased again at the beginning of
the epididymal tract. The analysis of expression within this tissue reflected that caput epididymis
exhibited the highest copy number for DEFB23, but the number of transcripts decreased in the
more distal parts of the duct. Figure 23 shows a comparison of DEFB23 expression among the
four different patients.
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Figure 23. Regional distribution of DEFB23 mRNA in different segments of human epididymis.
Total RNA from six different parts of epididymis from four different patients was isolated. After cDNA synthesis,
real-time quantitative RT-PCR (TaqMan) was carried out for each epididymal part. The copy number of transcripts
was normalized to hGAPDH (+/- SD in logarithmic scale).
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3.7.2 Study of DEFB27 expression along the male reproductive duct
The study of expression for DEFB27 in the male reproductive organ revealed that the relative
abundance of transcripts was much higher in epididymis than in the testicular tissues. This
distribution of expression contrasted with the expression pattern of the previously described
DEFB23. High constitutive expression along all parts of the epididymis peaking in the midpart
(corpus) was detected for DEFB27. Figure 24 shows a comparison of DEFB27 expression
among four different patients.
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Figure 24. Regional distribution of DEFB27 mRNA in different segments of human epididymis.
Total RNA from six different parts of epididymis from four different patients was isolated. After cDNA synthesis,
real-time quantitative RT-PCR (TaqMan) was carried out for each epididymal part. The copy number of transcripts
was normalized to hGAPDH (+/- SD in logarithmic scale).
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3.7.3 Study of DEFB29 expression along the male reproductive duct
DEFB29 together with DEFB27 exhibited a similar regional distribution in the male
reproductive tract. These two genes shared a similar chromosomal location, both mapping on the
same cluster, to be precise on the telomere of chromosome 20 (20p13). The relative abundance
of copies for DEFB29 was higher in epididymis than in testicular tissues. The general number of
transcripts for DEFB27 and DEFB29 along epididymis reached a higher level in comparison to
DEFB23 encoded on the centromere (20q11.1). Figure 25 shows a comparison of the expression
of DEFB29 among four different patients.
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Figure 25. Regional distribution of DEFB29 mRNA in different segments of human epididymis.
Total RNA from six different parts of epididymis from four different patients was isolated. After cDNA synthesis,
real-time quantitative RT-PCR (TaqMan) was carried out for each epididymal part. Copy number of transcripts was
normalized to hGAPDH (+/- SD in logarithmic scale).
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3.7.4 Expression profile of the novel genes and DEFB4 along the genital tract
A comparison of the profiles for the three novel β-defensin genes, together with the previously
described DEFB4 (RODRIGUEZ-JIMENEZ et al., 2003), revealed that DEFB4 exhibited a
comparable expression pattern, with the highest number of transcripts in the epididymal tract. On
the other hand, the relative mRNA abundance for DEFB4 and DEFB23 in epididymis was lower
than for DEFB27 and DEFB29. The highest copy number for DEFB27 and DEFB29 was
detected in corpus epididymis. In contrast DEFB23 mRNA was approximately one thousand-
fold less abundant in this epididymal region.
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Figure 26. Comparison of regional distribution for DEFB23, DEFB27, DEFB29 and the previously described
DEFB4 in different segments of human epididymis.
Total RNA from six different parts of epididymis from four different patients was isolated. After cDNA synthesis,
real-time quantitative RT-PCR (TaqMan) was carried out for each epididymal subunit. Copy number of transcripts
was normalized to hGAPDH (+/- SD in logarithmic scale).
All in all, the tendency of expression within the epididymal tract for DEFB4 and DEFB23 was
different to DEFB27 and DEFB29. It was shown that DEFB23 copy number decreased along the
more distal parts of the epididymal tract (Figure 26). The number of transcripts of DEFB27 and
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DEFB29 increased from caput to corpus epididymis although a slight reduction of expression
was also detected in the region of cauda epididymis. A notable difference of copies between
DEFB23 and DEFB29 in the distal cauda epididymis could be observed (Figure 26).
3.8 Studies on the regulation of DEFB23, DEFB27, and DEFB29
β-defensins have been found to be either constitutively expressed or induced by infection and
inflammation. Cell lines were stimulated with five inflammatory factors. After stimulation, RNA
was extracted and reverse transcribed to the corresponding cDNAs. The study was performed by
real-time quantitative RT-PCR (TaqMan). Eight stimulated cell lines from different organs were
studied, including: (HS-1, human normal testis) and (TE-671, human rhabdomyosarcoma)
obtained from testis and skeletal muscle respectively, tissues with high expression for the β-
defensins studied here. Some of the cell lines were included in the study since they showed
regulation for other previously described β-defensin genes. For instance, DEFB1 and DEFB2
(SEO et al., 2001) and DEFB3 (GARCIA et al., 2001-A) in HaCaT (keratinocyte cell line), DEFB4
in HEK293 (human embryonic kidney cells) and SAEC6043 (human small epithelial cells),
(GARCIA et al., 2001-B).
A549 (human lung carcinoma cells), EPLC (human epidermoid lung carcinoma), NCI-417
(small cellular bronchial carcinoma) were also included in the study. These cell lines were
obtained from tissues which are frequently colonized by pathogenic germs and β-defensins act as
antimicrobial agents (BALS et al., 1998). In each case, expression was undetectable or at the very
limit of detection. The number of transcripts was never higher than 25 copies but with a high
standard deviation.
Table 15. Regulation study of DEFB23, DEFB27, and DEFB29. Cells were stimulated with five different
inflammatory factors.
Inflamatory factors:  
TNF-α = [20 ng/ml]
LPS = [10µg/ml]
INTγ = [40 ng/ml]
PMA = [1µM]
IL-1α = [20ng/ml]
Control TNF-α PMA INT-gamma LPS IL-1
HS-1 0 0 0 0 0 0
NCI-417 0 0 0 0 0 0
HEK-293 0 (1-25) DEFB23 0 0 0 0
SAEC-6043 0 (1-25) DEFB29 (1-25) DEFB29 0 0 0
HACAT 0 0 0 0 0 0
EPLC 0 0 0 0 (1-25) DEFB29 (1-25) DEFB29
A549 (1-25) DEFB23 0 0 0 0 0
TE-671 (1-25) DEFB27 0 0 0 0 0
In addition, the expression of the three genes was also studied in two unstimulated cell lines
(HUH-7, RPMI2650). However, these cells did not show any basal expression for the new genes.
This study led to the conclusion that there was neither significant basal expression nor regulation
in the cell lines tested.
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3.9 Cellular localization in human testis and epididymis
To identify the exact location and the cell types that are responsible for the novel human β-
defensin gene expression in the epididymal tract, in situ hybridization was performed. The
experiments were carried out on testicular and epididymal sections. For this purpose, the full-
length cDNA of endothelin-1 (ET-1) (used as positive control), DEFB23, DEFB27, and DEFB29
were cloned into pGEM-T vector. The cDNA sequences were inserted into the vector in forward
and reverse direction in order to generate sense and antisense probes. The plasmids were
linearized using suitable restriction enzymes (Figure 27, A).
ET-1 and DEFB27 were cut using Not I, whereas DEFB23 and DEFB29 were linearized by
Pst I. After linearization, DIG-labeled RNA probes were generated using T7-RNA polymerase.
Efficiency of the in vitro transcription reaction was estimated by standard electrophoresis (2%
agarose gel), (Figure 27, B).
1 2 3 4
a b c d e f g h
A
3000 bp
1 2 3 4
a b c d e f g h
B
500 bp
300 bp
4000 bp
700 bp
Figure 27. Synthesis of DIG-labeled riboprobes.
Numbers 1, 2, 3, 4 correspond to DEFB27, DEFB23, DEFB29 and ET-1 respectively. Letters a, c, e, g indicate
sense probes and b, d, f, h, were assigned to antisense probes. (A) pGEM-T plasmids containing the inserts (total
expected size 3000 bp-3500 bp) were linearized by using restriction endonucleases (ET-1 and DEFB27 by Not I;
DEFB23 and DEFB29 by Pst I). Linear plasmids used to generate riboprobes were visualized on a 2% agarose gel
using standard electrophoresis. (B) Efficiency of riboprobe synthesis. The amount of the corresponding riboprobes
used during in situ hybridization was determined according to the results obtained by standard 2% agarose gel
electrophoresis. Expected size of riboprobes was between 300 bp and 700 bp.
The presence of endothelin-1 and endothelin receptors in human testis was probed by PERI et al.
For this reason this molecule was used as positive control. In situ hybridization was performed
on slices from human caput epididymis. Tissues were kindly provided by A. Prützmann, St.
Franziskus Hospital, Mönchengladbach, (Germany). The material was obtained from two
different patients suffering from testicular tumors. Subsequently, tissues were separated into
three different parts: lobuli testis, caput epididymis and cauda epididymis. Tissues were fixed in
4% paraformaldehyde and embedded in paraffin. Sections of 5 µm were spread on slides,
deparaffined, rehydrated and buffered with PBS. In situ hybridization was then performed (see
2.5.4). After hybridization of human epididymal sections with digoxigenin-labeled riboprobes, a
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secondary anti-digoxigenin alkaline phosphatase antibody was used to recognize the complex.
The hybridization was subsequently detected by a colorimetric reaction with two substrates
(BCIP and NBT) which form a reduction-oxidation system. In the particular cases of DEFB23
and DEFB27, the staining was restricted to the principal cells of the epididymal epithelium, but a
signal was also present in the negative control (sense probe), (data not shown). To resolve this
problem, several attempts to generate riboprobes using cDNA obtained (after the cloning
process) from one single clone were carried out, but similar results were achieved. An evaluation
of this investigation ended with no conclusive interpretation for these two β-defensins. However,
high expression of DEFB29 in the epithelial cell layer lining the lumen of the proximal caput
epididymis, was detected. A specific signal for DEFB29 antisense was located in dark color
within epithelial cells of human caput epididymis (Figure 28, a). In contrast, no signal was
detected in the negative control, performed with sense strand of DEFB29 riboprobe (Figure 28,
b).
Figure 28. Non-radioactive in situ hybridization of DEFB29 in human caput epididymis.
In situ hybridization in human caput epididymis was performed for DEFB29. Transverse sections of human caput
epididymis shows tubules with epithelial cells surrounding the lumen wherein the spermatozoa are located. The
amount of sense (5 µl) and antisense (5 µl) probes applied was adjusted according to the amount of riboprobe
determined by previous electrophoresis (Figure 27). Digoxigenin-labeled RNA probes of DEFB29 hybridized to
tissue slices being recognized by a secondary anti-DIG alkaline phosphatase antibody and detected with NBT/BCIP.
(a) Hybridization with the antisense probe. (b) Control with sense probe. Scale bars correspond to 50 µm. The
experiments were reproduced three times.
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Note that the apical granules of these cells were not labeled but appear dark. This is due to
refractivity light in both sense and antisense experiments. Control experiments, such as omitting
the probe or pretreatment with RNase A (100 µg/ml) (enzyme that destroys RNA), gave no
signal above background (data not shown).
In order to clarify the nuclear or cytoplasmic location of the signal, the state of conservation of
the cells after treatment as well as the cell distribution in the tissue, sections were treated with
DAPI (fluorescent dye that stains the nuclear DNA). DAPI allowed determination that the signal
was specifically located in the cytoplasm of the epithelial cell layer, lining the lumen of human
epididymis. Although the nucleus occupied most of the cell, a thin line is visualized at the outer
region (labeled by an arrow). Since the cytoplasm is around the nucleus, the staining was
detected all over the cell. Observe that, in general, the cells present an optimal state of
conservation after the in situ process. Non-epithelial cells are among tubules but did not present
a signal. The staining was localized in epithelial cells confirming the cellular specificity for the
detected DEFB29 mRNA. Experiments were repeated three times and similar results were
obtained.
A B
Figure 29. Location of DEFB29 mRNA in human epididymis.
Transversal sections (5 µm) of human caput epididymis show tubules with epithelial cells surrounding the lumen.
(A) Non-radioactive in situ hybridization based on the use of DIG-labeled RNA probes of DEFB29. This probe
hybridized to tissue slices being recognized by a secondary anti-DIG alkaline phosphatase antibody and detected
with NBT/BCIP. Positive signal for DEFB29 mRNA is located in the cytoplasm of epithelial cells surrounding the
epididymal lumen (B). On the same section, nuclear DNA was labeled using DAPI (1 mg/ml) and visualized by blue
color (fluorescence detection). Non-epithelial cells are visualized among the tubules (Figure 29, B) but lack staining
(Figure 29, A). Albeit the nucleus occupies most space inside the epithelial cell, the staining is located in the
cytoplasm which envelopes the nucleus. In the panoramic overview, the cytoplasmic staining is also detected as a
thin line in the extranuclear region (indicated by an arrow). Magnification × 20.
Additional experiments in lobuli testis and cauda epididymis were performed following the same
protocol. In the case of cauda epididymis, only background and no specific signal was detected
(data not shown). The glandular structure of the testis consists of numerous lobules. Within the
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basement membrane cells are arranged in several concentric layers lining the central lumen of
each individual lobule. The different germ cells may be seen in different stages of development.
In lobules testis, the antisense signal was slightly above sense background staining. This
situation impairs the analysis of the results and the identification of the different stained cells,
raising no conclusive interpretation.
Figure 30. In situ hybridization of DEFB29 in human lobule testis.
Transversal sections (5 µm) of tubules of human lobule testis. DIG-labeled RNA probe of DEFB29 hybridized to
tissue slices being recognized by a secondary anti-DIG alkaline phosphatase antibody and detected with NBT/BCI.
Staining produced in human lobule testis, with sense (A) and with antisense DEFB29 riboprobe (B). Putative
positive staining is indicated by an arrow. Magnification × 20.
3.10 Immunodetection of hBD4 in human epididymis
To detect and localize the presence of hBD4 in human epididymis, immunohistochemical studies
were accomplished on paraffinized sections using monoclonal antibodies (see 2.9). The detection
was performed by peroxidase staining. Antibodies for hBD23, hBD27 and hBD29 were not
available, but the monoclonal antibodies against hBD4 were ready to use. The use of this
antibody seemed to be reasonable since hBD4 presented a comparable expression pattern to the
new genes in human epididymis.
3.10.1 Selectivity and sensitivity of anti-hBD4 monoclonal antibodies
The characterization of antibody selectivity requires demonstration that the antibody binds
selectively to the protein that contains the immunogenic peptide.
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Western blot is a suitable procedure to check the selectivity of an antibody which should
recognize a single protein by visualization of a band at the appropriate molecular weight.
Therefore a specific reaction of the antibody with the peptide or protein used for immunization
(in comparison to related peptides) was performed by Western blot.
After immunization with a cyclic synthetic fragment of hBD4,
(ELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRK), several monoclonal antibodies
were obtained. During the antibody production, a first screening searching the positive clones
was performed by solid-phase ELISA. Antigen was applied to a microtiter-well containing
hybridoma supernatants (monoclonal antibodies). The selection system is based on a
colorimetric reaction and further measurement of the optical density by photometry. Using this
technique the following positive clones (hybridomas) were detected:
L1310D1, L1310D2, L1310G5, L1310G6, L1310A12, L1310H10, and L11135a-D12.
For further immunohistochemical analysis, sensitivity and selectivity of the undiluted
supernatant from the corresponding hybridomas were tested by Western blot. To study their
sensitivity, the synthetic peptide was applied to the gel in four different concentrations (3 ng,
30 ng, 100 ng, 300 ng) (see 2.8.2). After blotting, all the described antibodies were able to detect
3 ng (data not shown).
To test their selectivity, 100 ng of synthetic peptide (hBD1, hBD2, hBD3 and hBD4) were
confronted with each individual antibody (see 2.8.1). The results showed that the most specific
antibody was L1310G6. This monoclonal antibody recognized specifically hBD4 and did not
show crossreactivity with any other tested β-defensin (Table 16, line 3).
Table 16. Selectivity of anti-hBD4 monoclonal antibodies tested by Western blotting.
The symbols mean (-) lack of visible band. (+) Very faint band.+ Possible to appreciate a band. ++ Clear band. +++
Strong band.
Supernatant hybridoma hBD1 (100 ng) hBD2 (100 ng) hBD3 (100 ng) hBD4 (100 ng)
L1310D2 + + + +++
L1310G5 + (-) ++ +++
L1310G6 (-) (-) (-) +++
L1310H10 (+) (-) + +++
L1310A12 (-) (-) ++ +++
L1310D1 (+) (-) (+) +++
L11135aD12 + (+) + +++
To test the crossreactivity for the most specific antibody (L1310G6), an additional analysis was
performed. The selectivity was also studied by Western blot as previously described. The assay
was carried out by addition of the antibody to a membrane containing:
-The synthetic hBD1, hBD2, hBD3 and hBD4 (all of them in cyclic form).
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-The synthetic human β-defensins object of the present study: hBD27 (cyclic form), hBD23
(linear form), and hBD29 (linear form).
The L13-10G6 monoclonal antibody only recognized the synthetic hBD4 peptide in cyclic form
(Figure 31, column 4).
A
B
 1      2       3      4      5      6     7  1      2      3       4      5      6     7
Figure 31. Selectivity of monoclonal antibody L13-10G6.
Seven peptides were included in the study: (1) 100 ng hBD1 cyclic form; (2) 100 ng hBD2 (cyclic form); (3) 100 ng
hBD3 (cyclic form); (4) 100 ng hBD4 (cyclic form); (5) 100 ng hBD27 (cyclic form). (6) 100 ng hBD23 (linear
form); (7) 100 ng hBD29 (linear form). (A) After SDS-PAGE, Western blot showed that the bands were detected
only in column 4, where the cyclic form of hBD4 was applied. (B) Indian ink-stained membrane showed that seven
peptides were loaded and blotted. The experiment was performed in duplica.
3.10.2 Immunohistochemistry for hBD4
Immunohistochemistry is a powerful method for the identification of proteins in cells and
tissues. This method depends on the selectivity and sensitivity of the antibody binding to the
epitope of the protein used as immunogen.
To detect and localize the presence of hBD4 in human epididymis, immunohistochemical studies
were performed on paraffinized sections, using the anti-hBD4 monoclonal antibody (L1310G6).
The previously mentioned, anti-hBD4 monoclonal antibodies were also tested during this study.
The antibody that presented the clearest signal by immunohistochemistry (L1310G6) was also
the most specific antibody after Western blot evaluation.
Immunostaining was performed using the undiluted supernatant of hybridoma termed L1310G6
containing an anti-hBD4 monoclonal antibody. The staining appeared in at least three locations:
1-In the supranuclear Golgi region of basal epithelial cells.
2-In cytoplasmic accumulations close to the lumen. According to other reports these spots might
be cytoplasmic vesicles (GLICK and MALHOTRA, 1998).
3-Around the sperm.
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Figure 32. Immunodetection of hBD4 in proximal caput segment of human epididymis.
Immunohistochemistry of the caput region of human epididymis. The figures show tubules with the corresponding
epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue envelops the tubules.
(A and B) Binding of the specific undiluted supernatant containing the anti-hBD4 monoclonal antibody (L1310G6)
was visualized by a peroxidase reaction, resulting in brown deposits located in three different positions: (1)
Supranuclear Golgi region in basal epithelial cells. (2) Cytoplasmic accumulations. (3) In seminal plasma
surrounding the sperm located in the center of the tubule. Magnification, × 20.
Dilutions of the antibodies used are usually recommended as controls for testing the selectivity
of the staining in tissues. A dilution of 1/5 of the described monoclonal antibody L1310G6
against hBD4 was included in this study, showing a weaker positive signal.
A B
1
3 2
Figure 33. Immunodetection of hBD4 in distal caput segment of human epididymis.
Immunohistochemistry of the caput region of human epididymis. The figures show tubules with the corresponding
epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue envelops the tubules.
(A) Binding of the specific undiluted supernatant containing the anti-hBD4 monoclonal antibody (L1310G6) was
visualized by a peroxidase reaction, resulting in brown deposits located in three different positions: (1) Supranuclear
Golgi region in basal epithelial cells. (2) Cytoplasmic accumulations. (3) In seminal plasma surrounding the sperm
located in the center of the tubule (B) Staining detected by a 1/5 dilution of L1310G6 monoclonal antibody.
Magnification, × 20. A bright light filter was used for better comparison.
The proximal region of caput epididymis is closer to rete testis. The distal caput epididymis is
closer to corpus epididymis. Sections from proximal caput epididymis (Figure 32) presented less
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stained cytoplasmic spots in comparison to distal caput epididymis (Figure 33, A). The locations
in basal epithelial cells and around the sperm cells were also present in early sections. Controls
for the selectivity of an antibody are important for the correct interpretation of its localization in
cells and tissues. One control for selectivity is termed absorption or preabsorption. For this
control, the antibody is mixed with the protein or peptide used to generate the antibody, with the
objective to eliminate or reduce the binding of the antibody to the protein in the tissue.
Preincubation of the synthetic hBD4 (10 µg/ml, cyclic form) with the supernatant of hybridoma
containing the anti-hBD4 monoclonal antibody (L1310G6) was carried out. The antibody was
raised against the same hBD4 cyclic fragment used in preabsorption experiments. A specific
binding of hBD4-L1310G6 (Ag-Ab) was expected prior to the incubation on the sections. That
would result in less available antibody for recognizing hBD4 in tissues and therefore in a weaker
signal. Strikingly, a darker staining was detected, but also with more non-specific binding
(Figure 34, A). However, the same previously described positive locations identified by
L1310G6 were observed. Note that the signal in figure 34, A, is more intense in comparison to
figure 32. The signal was clearly amplified, especially for the cytoplasmic spots. The
experiments were repeated four times and similar results were obtained. In order to obtain more
information about this surprising result obtained by preabsorption, a similar experiment was
scheduled. A preabsorption experiment by incubating the synthetic peptide hBD1 (10 µg/ml,
cyclic form) with the anti-hBD4 monoclonal antibody (L1310G6) was carried out.
A B
Figure 34. Preabsorption of monoclonal anti-hBD4 antibody (L1310G6) with synthetic hBD4 (cyclic form)
and hBD1 (cyclic form).
Immunohistochemistry of transversal sections of human caput epididymis. The figures show tubules with the
corresponding epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue
envelops the tubules. Binding of antibody is visualized by a peroxidase reaction, resulting in brown deposits. The
preabsorption of antibody with antigen was performed prior to adding on the human epididymal sections.
Immunostaining obtained by immunohistochemistry occurred after the preabsorption of the monoclonal antibody
L1310G6 with hBD4 (cyclic form) (A) or hBD1 (cyclic form) (B). Magnification, × 20.
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According to the results obtained by Western blot, L1310G6 monoclonal antibody was specific
for hBD4 and did not detect hBD1. As expected, the results reflected that the staining appeared
in the same locations than those incubated exclusively with L13 10G6 and with a comparable
intensity (Figure 34, B).
Sections of human epididymis with cells containing a certain protein with demonstrated location
within the tissue, could be used to optimize the method. Endothelin-1 (ET-1) is a peptide
involved in eliciting smooth muscle cell with contractile activity in different tissues and organs,
including human epididymis (PERI et al., 1997).
A specific immunostaining for ET-1 was detected in the epithelial location within the epididymal
tract. For this reason this molecule was used as positive control. The present results are
consistent with those previously described within the epithelial cells of the human epididymis
duct wall (PERI et al., 1997). However, this work also showed a signal in apical spots (marked by
an arrow in figure 35).
Figure 35. Immunolocalization of ET-1 (positive control) in human epididymis.
Immunohistochemistry of transverse sections of human caput epididymis. The figures show tubules with the
corresponding epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue
envelops the tubules. Binding of antibody is visualized by a peroxidase reaction, resulting in brown deposits.
Positive immunostaining for ET-1 was detected in epithelial cells and in their apical spots (labeled by an arrow).
The selectivity of the immunohistochemical procedure was validated by negative controls which
ensured that the labeling method accurately identified the antibody bound to the tissue. Because
of the variety of background and non-specific labeling which are inherent in any
immunohistochemical analysis of cells and tissues, some negative controls were included.
The negative control slide consisted of a section which was treated identically to the rest of
slides but the primary antibody was omitted. The negative control slide was subjected to the
same epitope retrieval procedures (protease, microwave, etc.) as the primary antibody. The
Results                                                                                                                                                                          84
reason was to avoid that the epitope-preparation steps can significantly intensify endogenous
artifacts. The following negative controls were included in the study.
1-The intact culture medium Optimem was used as negative control, replacing the primary
antibody. This medium was applied, because Optimem was the tissue culture medium used to
culture the hybridoma whose supernatant contained the monoclonal antibody L1310G6. The
results showed that no specific signal could be detected using culture medium instead of primary
antibody.
2-An isotype IgG γ-1 from mouse was an additional negative control used to estimate the amount
of non-specific binding of mouse monoclonal antibodies to the human cell-surface and antigens
in human epididymis. The IgG γ-1 mouse antibody is the same type of immunoglobulin
(isotype), keeping the same three-dimensional structure of L1310G6, but it lacks specific regions
of antigen recognition. For this reason, the isotype IgG γ-1 should not recognize hBD4 in the
tissue. The use of this antibody resulted in no signal above background.
A B
Figure 36. Negative controls used in immunodetection of hBD4.
Immunohistochemistry of transversal sections of human caput epididymis. The pictures show tubules with the
corresponding epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue
envelops the tubules. The detection of the bound antibody is based on the visualization of brown deposits due to a
peroxidase reaction. (A) Negative control Optimem culture medium replaced the primary antibody, resulting in loss
of labeling. (B) The specific primary antibody was replaced by non-immune Isotype IgG γ-1 mouse antibody and
gave no staining above background.
Hybridoma supernatants (monoclonal antibodies) were screened by enzyme-linked
immunosorbent assay (ELISA) to detect positive clones, for example L1310G6 and L1310D1.
Since every antibody presents differences in the variable region, the results obtained with every
clone can differ substantially from one another. In fact, and in contrast to the positive results
shown by using the positive clone L1310G6, no specific signal was detected by anti-hBD4
monoclonal antibody L1310D1.
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Figure 37. Immunolocalization of hBD4 in human epididymis by monoclonal antibody L1310D1.
Immunohistochemistry of transversal sections of human caput epididymis. The pictures show tubules with the
corresponding epithelial cells surrounding the lumen wherein the spermatozoa are located. Interstitial tissue
envelops the tubules. The detection of the bound antibody is based on the visualization of brown deposits due to a
peroxidase reaction. After the test system ELISA, another monoclonal antibody (L1310D1) was considered as a
positive hybridoma. This clone was obtained after immunization with the same antigen (hBD4 cyclic form).
Sections incubated with anti-hBD4 monoclonal antibody L1310D1 showed no staining.
3.11 Evaluation of antimicrobial activity for hBD23, hBD27, and hBD29
3.11.1 Radial diffusion assay
Defensins have been defined so far as small cationic peptides that are crucial components of
innate immunity. The specific mechanism of antimicrobial activity involves permeabilization of
bacterial membranes (see 1.2).
Many studies have demonstrated that human β-defensins, e.g. hBD1 (VALORE et al., 1998),
hBD2 (TOMITA et al., 2000), hBD3 (GARCIA et al., 2001-A), hBD4 (GARCIA et al., 2001-B) are
antimicrobial agents. Antimicrobial activity of the new β-defensins was tested by radial diffusion
assay. The commonly used radial diffusion assay method is relatively simple to perform and is a
widely employed method in the laboratory since it provides semiquantitative or qualitative data
about the susceptibility of a given organism to a given agent. Experiments were repeated twice
and the results of this study showed that hBD27 (cyclic form) did not exert antimicrobial activity
against any of the tested bacteria, even at twice the concentration of the positive control. In
contrast, hBD23 and hBD29 (10 µg, linear form) presented antimicrobial activity against
Klebsiella pneumoniae DSM681, Pseudomonas aeroginosa 1128, Escherichia coli 1103, and
Escherichia coli 96440.
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Figure 38. Antimicrobial activity of the new β-defensins against four different bacterial strains.
The antimicrobial activity of hBD23, hBD27, hBD29 was evaluated by radial diffusion assay. The experiments were
fulfilled using three different concentrations of peptide (2 µg, 10 µg, 20 µg) and including three positive controls
MBI28 (10 µg), vancomycin (V) (10 µg) and doxycycline (D) (10 µg). The bacteria tested were Klebsiella
pneumoniae DSM681, Pseudomonas aeroginosa 1128, Escherichia coli 1103, and Escherichia coli 96440.
On the other hand, none of the new β-defensins presented significant antimicrobial activity
against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae DSM 11865.
Staphylococcus aureus 11729
hBD23 hBD27 hBD29            V            D       MBI 28
0
250
500
750
1000
2µg
10µg
20µg
10µg Control
Samples
Un
its
Streptococcus pneumoniae DSM 11865
hBD23 hBD27 hBD29           V            D      MBI 28
0
50
100
150
200
2µg
10µg
20µg
10µg Control
Samples
Un
its
Figure 39. Antimicrobial activity of the new β-defensins against two different bacterial strains.
The antimicrobial activity of hBD23, hBD27, hBD29 was evaluated by radial diffusion assay. The experiments were
fulfilled using three different concentration of peptide (2 µg, 10 µg, 20 µg) and including three positive controls
MBI28 (10 µg), vancomycin (V) (10 µg) and doxycycline (D) (10 µg). The bacteria tested were Staphylococcus
aureus ATCC 25923 and Streptococcus pneumoniae DSM 11865.
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3.11.2 Determination of the minimal inhibitory concentration
Minimal Inhibitory Concentration (MIC) is defined as the lowest concentration of drug that
inhibits more than 99% of the bacterial population. The determination of the minimum inhibitory
concentration (MIC) is apart from the radial diffusion assay, a second method for the
determination of the antimicrobial activity of a certain material. The MIC value represents the
reference for the antimicrobial effectiveness of a substance, being usually indicated in the
literature of an antimicrobial agent. For a group of antibiotics such as quinolones, or
aminoglycosides, a ratio of concentration: MIC 10 is required. This implies that a dose regimen
should be chosen which results in a serum or tissue concentration of at least 10 times the MIC.
The technique contributes information about the suitable concentration to be used. Failure to
achieve this concentration at the site of infection will lead to clinical and bacteriological failure,
and is likely to induce resistance to the entire class of antibiotic. The technique offers important
information about the antimicrobial potency of a substance. Several strains of bacteria were
included in the study for a better and complete overview of their antimicrobial potency.
Table 17. Minimal inhibitory concentration for hBD23.
Bacteria strain Gram staining MICMHB [µg/ml]
Staphylococcus carnosus TM300 + 18,8
Staphylococcus aureus ATCC25923 + 75
Streptococcus pneumoniae DSM11865 + 75
Escherichia coli DSM 1103 - 37,5
Klebsiella pneumoniae DSM681 - 75
Pseudomonas aeruginosa DSM 1128 - 150
Table 18. Minimal inhibitory concentration for hBD27.
Bacteria strain Gram staining MICMHB [µg/ml]
Staphylococcus aureus ATCC25923 + >300
Streptococcus pneumoniae DSM11865 + >300
Escherichia coli DSM 1103 - >300
Klebsiella pneumoniae DSM681 - >300
Pseudomonas aeruginosa DSM 1128 - >300
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Table 19. Minimal inhibitory concentration for hBD29.
Bacteria strain Gram staining MICMHB [µg/ml]
Staphylococcus carnosus TM300 + 37,5
Staphylococcus aureus ATCC25923 + >300
Streptococcus pneumoniae DSM11865 + >300
Escherichia coli DSM 1103 - >300
Klebsiella pneumoniae DSM681 - >300
Pseudomonas aeruginosa DSM 1128 - >300
The order of magnitude of 1-8 µg/ml is considered as an acceptable MIC value for clinically
relevant cationic peptide, described by HANCOCK (1997).
The present results show that, with the described techniques and in the range of the used
concentrations, hBD27 did not present any antimicrobial activity against the germs tested.
3.11.3 Hemolytic activity
Due to the fact that β-defensins base their antimicrobial activity in the interaction with the
membranes of bacteria, it is important to know whether these peptides can upset the membrane
of human cells.
The hemolytic activity of hBD23 and hBD27 was investigated in a hemolytic assay using human
erythrocytes in order to know the disruption or damage that these substances can cause to human
erythrocytes. A sensitive assay described by HELMERHORST et al., 1999 was used to study their
hemolytic effect (see 2.11).
The percentage of cell lysis produced by hBD27 was determined to be independent of the
concentration within the range of 10 µg/ml to 100 µg/ml. However, a slight increase was
observed with a concentration of 500 µg/ml. No significant hemolytic activity was noticed for
hBD27 in the range of the concentrations tested.
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Figure 40. Hemolytic activity of hBD27.
The hemolytic activity of hBD27 was analyzed by the measurement of free hemoglobin released by erythrocytes
after disruption. Free hemoglobin was determined photometrically in a microplate reader. Synthetic hBD27 (cyclic
form) was applied in different concentrations (1-10-50-100-500 µg/ml). MBI28 was used as positive control used
under the same experimental conditions. Test medium (1/10 TSB, 287 mM glucose, pH 7.4) was included as negative
control with complete absence of hemolytic activity. Experiments were repeated three times and similar results were
obtained.
The percentage of hemolytic activity for hBD23 depends on the concentration of peptide. The
application of 500 µg/ml of synthetic hBD23 (linear form) resulted in 80% of cell lysis.
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Figure 41. Hemolytic activity of hBD23.
The hemolytic activity of hBD23 was analyzed by the measurement of free hemoglobin released by erythrocytes
after disruption. Free hemoglobin was determined photometrically in a microplate reader. Synthetic hBD27 (cyclic
form) was applied in different concentrations (1-10-50-100-500µg/ml). MBI28 was used as positive control used
under the same experimental conditions. Test medium (1/10 TSB, 287 mM glucose, pH = 7.4) was included as negative
control with complete absence of hemolytic activity. Experiments were repeated three times and similar results were
obtained.
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4. Discussion
The aim of this study was to identify and characterize novel human β-defensins, a family of
cationic peptides considered as antimicrobial agents. At the start, the investigation was focused
on the search for new genes containing the characteristic six cysteine motif of the β-defensin
family by in silico screening of genomic sequences. After discovering three novel genes
(DEFB23, DEFB27, and DEFB29), description, expression and regulation of the genes as well as
the location and biological role of the putative peptides in the human organism were scheduled
and performed. The interpretation of the results obtained is presented in the following chapters.
4.1 Features of the new genes and their corresponding amino acid sequences
Genome sequencing efforts are revolutionizing biomedical science. The relevance of functional
genomics in modern science has become more important since the Human Genome Project
(HUGO) was completed. Functional genomics involves high throughput techniques and
bioinformatical tools that facilitate the prediction of the biological function of genes and proteins
(or parts of them) based on structural data.
Using this scientific strategy, the present work reports the discovery of three new human β-
defensins, named  DEFB23, DEFB27, and DEFB29. The novel genes were identified by the
analysis of genomic sequences (see 2.13 and 3.1). The new genes are mapping on chromosome
20 in two different clusters. DEFB27 and DEFB29 are clustered at the telomere (accession
number of the contig: AL360078) and DEFB23 at the centromere (accession number of the
contig: AL121751) of the chromosome. This location differs from the chromosomal location of
human defensins described so far, which are encoded in the chromosomal region 8p23. The
genes encoding the leukocyte α-defensins (HNP) are comprised of three exons (KAISER and
DIAMOND, 2000). The α-defensins HD5 and HD6 consist of two exons, which are equivalent to
exons two and three of the leukocyte α-defensins (QUAYLE et al., 1998). The new β-defensins
(DEFB23, DEFB27, and DEFB29) exhibit the same genomic organization as other β-defensins
previously described (DEFB1, DEFB2, DEFB3, DEFB4, and DEFB6), with two exons flanking
an intron that differs in length for every new β-defensin. However, DEFB5 consists of three
exons like the above-mentioned leukocyte α-defensins. The gene structure of the β-defensins
suggests a second subdivision of the family (KAISER and DIAMOND, 2000). One subfamily,
which includes DEFB2, contains a relatively small (2 kb) intron. The other subfamily includes
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DEFB1 with a large intron (6972 bp). Interestingly, DEFB27 and DEFB29 show a much shorter
intron (1000-2000 bp) in comparison to hBD23 (6000-7000 bp) (Table 14) which is encoded in a
different chromosomal location (Figure 17). According to the classification proposed by Kaiser
and Diamond, DEFB27 and DEFB29 might be included in the first subfamily, whereas DEFB23
would be in the second.
A comparison to the genomic sequences reveals that the novel cDNAs correspond to transcripts
from two exons, wherein the signal peptide is encoded by the first exon and the cysteine-
containing core structure by the second (Figure 13, Figure 14, and Figure 15).
HE2 was characterized as an epididymis-specific secretory protein, originally identified during a
screening for epididymis-specific transcripts (OSTERHOFF et al., 1994). HE2 undergoes different
splicing events leading to nine variants. Three variants (HE2C, HE2ß1, and HE2E) share the
characteristic β-defensin cysteine pattern (VAN HORSTEN et al., 2002). The HE2ß1 variant
contains three exons and is located on chromosome 8, between DEFB3 and DEFB4 (Figure 6).
Thus, it is reasonable to propose that chromosomal location does not necessarily predict genetic
structures.
The corresponding exon-intron boundary regions of DEFB23, DEFB27, and DEFB29 exhibit
conserved splicing sites (Figure 16). Therefore, the RNA of these defensins might be processed
by a similar splicing machinary.
Fragments of DNA encoding the classical six cysteine pattern of β-defensins, termed DEFB16
and DEFB22, were found in a centromeric contig of chromosome 20 (Figure 17). These
sequences were considered as pseudogenes since neither ESTs searched in silico in public
domain servers, nor amplification products following RACE-PCR were detected. These
pseudogenes might not be expressed because during evolution they might have lost their
physiological role in the organism.
The structural comparison of amino acid sequences is based on the results obtained in silico with
the signal peptide prediction program (SignalP) and the alignment of the amino acid sequences
deduced from the corresponding cDNAs. The amino acid sequences of hBD23, hBD27, and
hBD29 were compared to the sequences of hBD1, hBD2, hBD3, hBD4, hBD5, hBD6, the
mentioned pseudogenes, as well as two splicing variants of HE2 (HE2C and HE2E) (Figure 18).
It is interesting to note that a glutamic acid residue, in fourth position carboxy-terminally located
after the third cysteine, is conserved in most of them (including the new β-defensins). This
glutamic acid is also conserved in the α-defensin family (Figure 2). Few conserved residues have
been indicated, except the cysteine motif, between the α-defensin and β-defensin family.
Nevertheless, it has been questioned whether the two families have descended from a single
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ancestral gene. This common feature would contribute to supporting the evolutionary continuity
between both families.
According to the results obtained by bioinformatical search using the SignalP server, the novel
hBD23, hBD27, and hBD29 peptides contain secretory signal peptides indicating that they are
amino-terminally processed and secreted from the cells.
In contrast to the primary structure of published β-defensin peptides (whose genes are mapping
on chromosome 8p23) and hBD23 (encoded in centromeric region of chromosome 20q11.1), the
new β-defensins hBD27 and hBD29 (chromosome 20p13) exhibit long carboxy terminal
extensions following the β-defensin-specific cysteine core (Figure 18). These carboxy-terminal
prolongations differ significantly in amino acid composition and do not exhibit homology with
other sequences. For α-defensins, amino-terminal cationic prosequences are known to serve as
regulatory domains (WILSON et al., 1999), but the contribution of carboxy-terminal elongations
to β-defensin function remains to be analyzed. Therefore, the isolation of the native peptides
corresponding to the new β-defensins genes would be an important achievement.
4.2 Tissue distribution and regulation of the novel β-defensins
Examination of the expression pattern and tissue distribution of the new β-defensins was
performed by using real-time quantitative PCR (TaqMan), resulting in the quantification of their
relative transcription levels in 28 human tissues. Interestingly, only very few tissues show
expression of the novel β-defensin genes. The three genes described here show the highest
expression in the male reproductive organ (human testis and epididymis) and a considerable
level of transcripts in skeletal muscle (Figure 22). The expression of DEFB29 is confined to
these two organs (Figure 21). Beside these two organs, DEFB23 is expressed at lower levels in
lung and trachea, tissues that also express other defensins (ZHAO et al., 1996; BALS et al., 1998)
(Figure 19). Aside from the male reproductive organ and skeletal muscle, DEFB27 is expressed
in kidney (Figure 20). Renal expression for DEFB1 (VALORE et al., 1998) and the murine
homologue mBD-1 (MORRISON et al., 2002) was proposed to provide protection against urinary
tract infection.
The expression of DEFB27 is more widespread over different tissues in comparison to the other
two human β-defensins whose expression is detected in very few tissues and therefore with a
higher spatial selectivity for developing their still unknown physiological functions. The
expression analysis shows that none of the newly described β-defensins are constitutively
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expressed in skin, as would be expected for peptides primarily involved in innate immunity
(Figure 22).
The expression in the male reproductive organ is consistent with the results obtained in other
investigations. For instance, recent publications show that hBD1 is expressed in testicular tissue
and is present in ejaculated spermatozoa and the seminal plasma (COM et al., 2003). Another
investigation shows that the rat β-defensin 1 (RBD-1) is expressed in caput epididymis
(PALLADINO et al., 2003). Recent studies indicate that DEFB4 is highly expressed in the male
reproductive tract (GARCIA et al., 2001-B). The high level of DEFB4 expression in testicular
tissue is attributed to the fact that during the extraction of RNA from testis, epididymal tissue
was possibly included.
The mentioned studies, together with the recently described DEFB5 and DEFB6, which are
specifically expressed in human epididymis (YAMAGUCHI et al., 2002), reinforced the necessity
of a more detailed study of expression within human epididymis. The present work achieves this
demand and provides evidence that the novel members of the β-defensin family described here,
show a distinct expression in the male genital tract, especially in functionally different segments
of human epididymis. A global quantitative comparison of the expression profiles in the genital
tract for the three new genes was performed. Along the organ, the expression of DEFB4 and
DEFB23 exhibits a different tendency in comparison to DEFB27 and DEFB29 (Figure 26). The
absolute abundance of mRNA in epididymis for DEFB4 and DEFB23 is lower than for DEFB27
and DEFB29. These results might be attributed to their different chromosomal location. On the
other hand, this epididymal expression does not seem to be directly associated with their
antimicrobial function, since DEFB27 was highly expressed in epididymis but did not exhibit
antimicrobial activity (Figure 38 and Figure 39). Thus, some β-defensins might be mere
antimicrobial peptides but this analysis suggests other putative roles for some of the new
members of this peptide family.
In general, the epididymis displays a highly region- and cell-specific pattern of gene expression
(RODRÍGUEZ et al., 2001; ORGEBIN-CRIST et al., 1995). Sperm maturation is accompanied by
distinct temporal and spatial gene expression along the epididymis (KRULL et al., 1993; PERA et
al., 1994). Region-specific gene expression in the epididymis implies regionalization of
regulatory mechanisms (KIRCHHOFF et al., 1997; KIRCHHOFF et al., 1999). This specific
regionalized expression, as was previously proposed for other β-defensin related peptides
(FROHLICH et al., 2001; LI et al., 2001), may contribute to generate the optimal conditions and
the necessary microenvironment for sperm maturation, storage and progression. Only recently,
theories have been developed about how and when, during ontogenesis, this pattern formation
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takes place and what its significance might be. The functional significance of the regional
expression and the post-testicular modifications of the sperm surface occurring within the
epididymis is still unclear. The order with which the sperm surface comes into contact with
epididymal secretory proteins may be important for the resulting molecular and physiological
effects. In fact, Chimpanzee spermatozoa obtained from the caput epididymis are immotile and
unable to bind or to penetrate the ovum, but acquire these abilities when they reach the caudal
region (GOULD and YOUNG, 1990).
The constitutive expression in skeletal muscle of all the newly described β-defensins is also
known from the murine defensin mBD-6 (YAMAGUCHI et al., 2001). This location is rather
surprising, since this organ is not a frequent target for bacterial pathogens. A specific
fluorescence for actin, alpha-actinin, and tropomyosin was detected in the principal cells of the
bovine epididymal epithelium (YAGI et al., 1992). These molecules are also structural
components of the skeletal muscle. Similarities in the location for contractile proteins and
defensins suggest further investigations, most importantly immunohistochemical assays to
elucidate the exact location of the new defensins within this tissue. Such an investigation will
help to elucidate the whys and wherefores of skeletal muscle expression.
It is known that certain peptides are produced in large quantities at sites of infection or
inflammation, and their expression can be induced by bacterial products such as endotoxic
lipopolysaccharide (LPS) and proinflammatory cytokines such as tumor necrosis factor α
(TNF α). Concerning the regulation of the human β-defensin family, DEFB1 has been
considered to be constitutively expressed in kidney and in epithelia of the female urogenital tract
(VALORE et al., 1998). However, in blood cells, the expression of this gene was enhanced after
stimulation by lipopolysaccharide or bacterial cells (FANG et al., 2003). Other authors have
assumed that, due to the low levels of DEFB1 expression, regulation of DEFB1 is not conclusive
(KING et al., 2002). DEFB2 can be induced in various epithelial tissues by inflammatory
cytokines (BECKER et al., 2000), or by bacteria and fungi (HARDER et al., 1999). On the other
hand, DEFB3 and DEFB4 reside in epithelial but also in non-epithelial tissues and they can be
induced by different inflammatory factors. In fact, DEFB3 is induced in certain cell lines by
TNF α and bacteria (HARDER et al., 2001), as well as by γ-interferon (GARCIA et al., 2001-A).
Recent results show that the expression for DEFB4 is inducible in lung epithelial cells by
addition of PMA (GARCIA et al., 2001-B). Further evidence regarding the varying inducibility
for every defensin is the inhibition of mRNA expression for DEFB3, but not for DEFB1, and
DEFB2, by corticosteroids, hormones that control epididymal function (DUITS et al., 2001).
Related to this is the fact that two β-defensin-like peptide sequences (HE2ß and HE2γ) are
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members of an epididymis-specific family of androgen-regulated proteins (HAMIL et al., 2000).
In the rat, androgens can regulate the expression of RBD1 in the initial segment of epididymis
and caput, but not in corpus or cauda (PALLADINO et al., 2003). These authors suggested an
antimicrobial role in the testis and epididymis.
The expression of the three new β-defensin genes mapping on chromosome 20 was tested in cell
lines from different organs, including those which exhibited expression for other previously
described β-defensins. The tested cell lines showed no basal expression (Table 15). These results
suggest that their expression is confined to a certain and specific cell type. It may also be due to
the fact that, since defensin expression is widely androgen-dependent, the genes might be down-
regulated under cell culturing conditions.
4.3 Cellular location of defensins in epididymis
Previous evidence demonstrated that hCAP-18 is located in the epithelium of human epididymis
and in seminal fluid. This human cationic peptide was described to be attached to spermatozoa,
assuming a role in conception (MALM et al., 2000).
The evaluation of tissue distribution achieved in this work reflects the importance of another
group of cationic peptides, the ß-defensins in the male reproductive tract. To localize their
specific sites of expression, in situ hybridization was performed in caput and caudal regions of
the adult human epididymis as well as in lobuli testis.
The present work demonstrates that the mRNA of DEFB29 is restricted to the epididymal duct
epithelium of human caput epididymis (Figure 28). As proposed, DEFB1 was located in
epithelial cells of human secretory glands (ZHAO et al., 1996). A recent publication demonstrated
that in mice, the hybridization signal of the mBD-12 antisense probe is also confined to the
epithelial cells of the epididymis caput mid/distal segment. No signal for mBD12 was detected in
the corpus or caudal region (YAMAGUCHI et al., 2002). In situ hybridization showed that HE2 (β-
defensin-like peptide) was present exclusively in the epithelial cell layer of the epididymal duct
but not within the lumen, nor in peritubular muscle, nor in intertubular tissue (OSTERHOFF et al.,
1994). Epithelial cells represent more than 80% of the cell population of the epididymal
epithelium and play an important role in luminal protein secretion (HERMO et al., 1994). Due to
the fact that the novel β-defensins contain secretory signal peptides, it is reasonable to speculate
that they are secreted into the epididymal lumen wherein the sperm migrate.
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Epididymis is anatomically continuous to the urethra and is always at risk of ascending
microbes. Thereby these cells may express and produce the necessary antimicrobial peptides to
protect the spermatozoa from invasive infections.
Besides storage, a major function of the epididymis and its corresponding epithelial cells is the
disposal of factors to create a microenvironment enabling the spermatozoa to bind and to fertilize
eggs, a process which is known as maturation (CORNWALL et al., 1995). Without these specific
alterations, spermatozoa lack forward motility and the capability to fertilize (YANAGIMACHI et
al., 1994). Thus, it is possible that the epithelial cells express, synthesize and secrete β-defensins
to contribute to this process.
In situ hybridization experiments performed for DEFB29 in lobuli testis show a signal with the
antisense probe (Figure 30). Nevertheless, these results were not conclusive since a weaker
staining was also detected in sections treated with the sense probe (Figure 30). Some genes from
the testis as well as other tissues may be transcribed in both directions, creating both sense and
antisense RNA (Knee et al., 1994; Ivell et al., 1998). Moreover, this result might be reinforced
by the fact that hBD1 was immunolocated in the testicular interstitial compartment (Leydig cells)
and in seminiferous tubules (pachytene spermatocytes and spermatogonia) (COM et al., 2003).
4.4 Immunolocation of human β-defensins in the male reproductive tract
Using a monoclonal anti-hBD4 antibody (L1310G6), hBD4 was located in the male genital
organ. The peptide was detected by immunohistochemistry in three different locations (Figure 32
and Figure 33):
First, the peptide was located in basal regions of epithelial cells of human epididymis. The
endoplasmatic reticulum (synthesis of peptides) and Golgi apparatus (storage of peptides) are in
the direct vicinity of the nucleus which is basally located within these cells.
Second, the peptide was detected in cytoplasmic spots of epithelial cells. According to other
reports these accumulations might be cytoplasmic vesicles (GLICK and MALHOTRA, 1998).
Third, the peptide was observed surrounding the sperm contained in the epididymal lumen.
These discoveries suggest that the trajectory of the peptide begins in the endoplasmatic reticulum
and is subsequently stored or modified in the Golgi apparatus. The vesicles migrate from the
perinuclear basal region, through the cytoplasm and after evagination of the cytoplasmic
membrane, the peptide are secreted into the lumen wherein the sperm migrate. This theory is in
agreement with previous reports (NOVICK et al., 1981).
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Figure 42. Putative subcellular trafficking of hBD4 in epithelial cells of human caput epididymis.
Proteins destined to be secreted move through the secretory pathway in the following order: rough ER → Golgi
cisternae → secretory or transport vesicles → cell surface (exocytosis) →epididymal lumen (wherein the sperm
migrate). Discontinuous arrow indicates the putative progression of the peptide.
The first location of the immunostaining was the basal position in epithelial cells of human
epididymis. This result is in agreement with other reports that demonstrate the perinuclear
location of HE2β1 (β-defensin-like peptide) (HAMIL et al., 2000). The authors relate the basal
location with the position of the Golgi complex. In contrast, one antibody (P4) specifically
directed against HE2β1/HE2E (β-defensin-like peptides) located the peptides in the apical part of
the epididymal epithelium (VON HORSTEN et al., 2002).
ESP.13.2, the Macaca fascicularis homologue of DEFB26, is stored in the principal cells of the
epididymal epithelium. In this case immunofluorescence was present in both apical and basal
locations (PERRY et al., 1999).
A second positive staining for hBD4 was observed in apical cytoplasmic spots within the
epithelial cells close to the lumen. These cytoplasmic accumulations might be vesicles that
transport or secrete peptides (GLICK and MALHOTRA, 1998). The sperm migrate within the
lumen, wherein presumably the peptide is supposed to be released by these vesicles. It was
observed that early sections of proximal caput epididymis contained less stained vesicles (Figure
32) in comparison to distal caput epididymis (Figure 33). The proximal segment is closer to rete
testis, whereas the distal segment of caput epididymis is closer to the corpus epididymis. It has
been demonstrated that corpus epididymis presents a much higher expression level of DEFB4
than rete testis (RODRIGUEZ-JIMENEZ et al., 2003). These results suggest a correlation between
the transcriptional level of DEFB4 along caput epididymis and the biosynthesis of hBD4. To
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know if these vesicles are involved in exo- or endocytosis, electron microscopy would be
required.
The considered third location for hBD4 is around the sperm, which moves along the epididymal
tubular duct. This result is supported by other investigations: HE2ß1 (β-defensin-like peptide)
was shown to be expressed in epithelial cells and was observed to be specifically bound to the
sperm surface in the postacrosomal and neck regions (HAMIL et al., 2000). The immunostaining
of hBD1 was also detected on the head portion of spermatozoa (COM et al., 2003). This is a
rather unexpected fact for an antibacterial peptide involved in the innate immunity, unless it is
protecting the sperm.
To test the selectivity of the antibodies, a preabsorption control was included in
immunohistochemical studies. Nevertheless, this absorption control cannot determine whether
the protein bound to the tissue is the same protein that is used for preabsorption. This control
consists in a preabsorption of the synthetic peptide used for immunization of the animal with the
resultant monoclonal antibody. The expected result would be to detect less signal, since the
recognition of the peptide by the antibody should leave less antibody available for staining on the
specimen. However, the absorption control can produce staining even though the antibody is
specific for the peptide or protein. A complete inhibition of antibody binding to the tissue is
difficult. For instance, a small but significant dissociation of the complex antigen-antibody
occurs during the incubation.
The interpretation of the results obtained after the preabsorption experiment (Figure 34) is
controversial. The preabsorption might create an amplification system. This idea is also
supported by other investigators. For instance, it was proposed that albeit unbound primary
antibody could have provided the signal, the majority of the labeling occurred because the
antibody-protein complex bound to the tissue (Burry, 2000). The author proposed that, after
antibody binding, other parts of the protein are available to interact with cytoplasmic proteins in
the tissue sections. Then, the protein linked to the antibody binds to the tissue by protein-protein
interactions. The strength of this complex could be stronger than a simple protein-antibody
binding. When an antibody binds to two separate proteins, the reactions of protein-antibody are
thermodynamically slower than those occurring with single proteins. This fact favors protein-
protein interactions in the tissue. Thereby, the probability of interacting with endogenous
proteins is higher and would explain why the distribution of the endogenous protein is amplified.
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The presence of anti-sperm antibodies (ASAs) has been associated with infertility (RUMKE et al.,
1959; BRONSON et al., 1984). ASAs may impair the function of sperm by recognizing antigens
involved in fertility (BRONSON et al., 1987). The identification of the antigens to which ASAs are
directed is important for understanding their importance in fertilization. One of these antigens
located in rat epididymis was recently identified and named E3 (RAO et al., 2003). This peptide,
with the characteristic six cysteine motif of β-defensins has been considered as a potential
element in fertility (RAO et al., 2003). The analysis of the secondary structure in mature E3
showed a terminal alpha helical barrel followed by three β-sheets. This structure is also shared
by hBD2. These similarities reinforce speculations on the alleged role in fertility of β-defensins.
The fertilization process is the result of a complex sequence of events that collectively result in
the fusion of the opposite gametes. The male gamete undergoes continuous morphological and
biochemical modifications during sperm development in the testis, maturation in the epididymis,
and capacitation in the female reproductive tract. Only capacitated spermatozoa are able to
recognize and bind to the ovum's extracellular coat, the zona pellucida (ABOU-HAILA and
TULSIANI, 2000). The capacitation and binding processes require the presence of proteins and
glycoproteins and their receptors on the surface of the zona pellucida (YANAGIMACHI, 1994). An
increase in the fluidity of the plasma membrane of sperm cells could facilitate the installation on
the surface of spermatozoa of new proteins and glycoproteins during the epididymal transit
(COOPER, 1995). The exocytosis of the acrosomal contents of sperm cells is believed to be a
prerequisite that allows the spermatozoa to penetrate the zona pellucida and fertilize the ovum
(TULSIANI, 2000). It remains to be shown whether the newly described β-defensins bind to
spermatozoa. In this context, it is interesting to note that hBD-3 is capable of inducing reversible
ion currents in Xenopus laevis oocytes (GARCIA et al., 2001-A). At high concentrations,
antimicrobial peptides exhibit more antibiotic activity than cytotoxicity for murine oocytes, and
this could be related to the natural, sperm cell-induced perforation of the oocyte membrane
(SAWICKY and MYSTKOWSKA, 1999). However, the functional significance of all these findings
remains to be determined. To study whether these peptides create a suitable microenvironment to
store the sperm under optimal conditions, act on the membrane of germinal cells or have
influence on sperm-motility, a combination of β-defensins would be advisable.
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4.5 Antimicrobial activity
Defensins have been reported to exhibit powerful antiviral, antifungal, and antibacterial activity
against a wide variety of microorganisms (LEHRER et al., 1985; WEINBERG et al., 1998; LEHRER
et al., 1989). The innate immune response comprises the first line of host defense against
pathogenic microorganisms and it is commonly believed that β-defensins are components of this
immunity as a characteristic that identifies them.
It has been demonstrated that human β-defensins e.g. hBD1 (VALORE et al., 1998), hBD2
(TOMITA et al., 2000), hBD3 (GARCIA et al., 2001-A), and hBD4 (GARCIA et al., 2001-B) are
antimicrobial agents. The mechanism by which defensins act as antibacterial agents has been
analyzed previously (see 1.2) and seems to involve the bacterial cell membrane and intracellular
targets (XIONG et al., 1999).
Because the epididymis is anatomically continuous to the urethra, it is always at the risk of
ascending microbial invasion. Acute epididymitis is a common sexually transmitted disease,
caused by bacterial infection of the epididymis (YAMAGUCHI et al., 2002). The mechanisms that
protect genitourinary organs from ascending infection by microbes are only partially understood.
Since most mucosal surfaces do not normally contain abundant phagocytic cells, one would
expect that epithelial cells and their secretions directly interfere with microbial colonization and
invasion. The fight against urethral ascending bacterial infections in the male genital organ is
very important, because this infection is a frequent cause of infertility after epididymitis.
Therefore, host defense against bacterial pathogens would be very important in the epididymis
for the protection of spermatozoa. The presence of antimicrobial substances in the epididymis,
the major storage site of spermatozoa, might be related to germ cell protection from invading or
sexually transmitted microorganisms. Bin1b (the rat homologue of HE2E) shares the β-defensin-
specific cysteine pattern and was shown to be expressed in caput epididymis (LI et al., 2001).
For this protein, experimental evidence of an antimicrobial effect was provided, and it was
assumed that Bin1b prevents the ascent of microorganisms into the adjacent testis.
Other β-defensins show expression in the male reproductive organ. In fact, the expression of
hBD1 was determined in seminiferous tubules, to be precise in spermatogonia, pachytene
spermatocytes and early spermatids. The peptide was located by immunohistochemistry on the
head of the sperm (COM et al., 2003). The authors suggested that the spermatozoa contribute to
their own defense in the male and female reproductive tract. Moreover, hBD4 is expressed in the
male genital organ and exhibits antimicrobial activity (GARCIA et al., 2001-B). DEFB23 and
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DEFB29 are expressed in epididymal tissue and the synthetic peptides, corresponding to the
predicted mature peptides, showed antimicrobial activity. These peptides may be involved in
sperm protection from microbial pathogens.
The composition of the amino acid sequences might be crucial for their antibacterial activity and
spectra. The enhanced microbicidal activity observed for α-defensins (HNP), with two basic
residues at both the N- and C-termini, could be due to optimization of the amphiphilicity of the
structure, which could facilitate specific interactions with the microbial membranes (RAJ et al.,
2000).
However, these aspects do not explain the differences in the antimicrobial activity of the new
human β-defensins. In fact, the hBD23 and hBD29 (synthetic peptide) contain an equivalent
number of acid residues at N- and C- termini in comparison to hBD27 (Figure 18). Nevertheless,
hBD23 and hBD29 presented antimicrobial activity whereas hBD27 was completely inactive
against the tested germs (see 3.11).
On the other hand, it has been suggested that a highly positive net charge in the cysteine core
region is a prerequisite for antimicrobial action (HWANG et al., 1998). Synthetic hBD23 contains
the most positive charge within the cysteine motif, reflecting more efficient antimicrobial
activity. The synthetic hBD29 contains less amino acids with positive charge within this region
(Figure 18), presenting a weaker antimicrobial activity. Moreover, hBD27 comprises the least
positive charge and is completely inactive against the tested germs. However, with the present
results it is not possible to affirm that hBD27 is not an antimicrobial agent. This peptide might
show efficiency against other non-tested bacteria, but the results lead to the conclusion that
hBD27 is not a broad spectrum antibiotic. Interestingly, following the cysteine core, the
additional C-terminal prolongations of hBD27 and hBD29 contain more acidic than basic
residues (Figure 18), providing an overall negative charge. From the antimicrobial point of view,
this aspect would not explain the presence of such long extensions. The influence of these
elongations in the biological effect of the new β-defensins still remains unknown. The results do
not permit a unique evaluation of their meaning, since different influences in vivo like peptide
induction, synergism, and salt dependency might play an important role in the final effect.
The selective toxicity of antibiotic peptides is thought to be due to the composition of the
bacterial membrane which contains anionic phospholipids. In contrast, the presence of
zwitterionic phospholipids and cholesterol in mammalian cell membranes could prevent
interaction with the peptides and avoid host tissue damage (BOMAN et al., 1993; BOMAN et al.,
2000, MATZUSAKI et al., 1999). However, it has also been demonstrated that antimicrobial
peptides can damage eukaryotic cells (LEHRER et al., 1992; LEHRER et al., 1993; LEHRER et al.,
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1994). It is commonly believed that the activity of the β-defensin family as antimicrobial agents is
based on their interaction with bacterial membranes (LEHRER et al., 1992). However, defensins
appear to be electrostatically specific for prokaryotic cells (WEINBERG et al., 1996). Nevertheless, it
is of interest to know how the new peptides interact with human cells e.g. erythrocytes. The
evaluation of the hemolytic activity shows different results for hBD23 (some hemolytic effect) and
hBD27 (no significant hemolytic effect). Since hBD27 does not kill bacteria or destroy
erythrocytes, it is possible that hBD27 lacks the ability to disrupt membranes. This peptide seems to
lack antimicrobial activity. The ability to act as antimicrobial agents has been considered as the
hallmark that characterizes this family of cationic peptides. Moreover, the new members of the
β-defensin family are distinctively expressed or located in human epididymis, an organ involved
in storage and maturation of sperm. Therefore, the present work introduces new perspectives that
can also be of interest for researchers with expertise in fields beyond innate immunity.
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